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Collin-Jamal Smith: T cells and their cytokines are critical for pathogenesis in spontaneous 
autoimmune peripheral polyneuropathy. 
(Under the direction of Maureen A. Su) 
 
The immune system defends the body from pathogens, and its function is essential for 
life. Adaptive immunity protects the host through specific targeting and elimination of pathogens 
and toxins. However, due to the stochastic nature of adaptive immune cell antigen specificity, 
cells that attack the host are inadvertently generated. Autoimmunity, or immune attack against 
the host, causes severe morbidity and mortality in the population. Furthermore, treatments of 
autoimmune diseases often have limited efficacy and serious side-effects. To develop better 
treatments for autoimmunity, the underlying pathogenesis must be understood. For my thesis, I 
studied a mouse model of chronic inflammatory demyelinating polyneuropathy (CIDP) to 
understand the mechanisms behind disease. CIDP is a debilitating condition caused by 
autoimmune demyelination of peripheral nerves. In my studies, I researched the role of T 
lymphocytes, the immunosuppressive cytokine interleukin 10 (IL-10), and other immune cells 
and markers in NOD.AireGW/+ mice that develop spontaneous autoimmune peripheral 
polyneuropathy (SAPP) that resembles CIDP. I demonstrated that T cells are required for SAPP, 




I delineated a novel mechanism in which IL-10-induced STAT3 increases S1pr1 
expression and CD4+ T cell migration to accelerate T cell-mediated destruction of peripheral 
nerves. My results suggest the increased IL-10 expression observed in CIDP patients may be a 
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CHAPTER 1: INTRODUCTION 
1.1 Immune system structure 
The immune system defends the body from deleterious organisms, and its function is 
essential for life. Components of the immune system target and destroy potentially harmful 
entities by discriminating between “self”, as in the host, and “non-self”, as in of foreign origin. 
Non-self includes microbes, allografts, and xenografts. The immune system further protects the 
body by identifying and eliminating abnormal self, which occurs in cancer and viral infection. In 
order to manage the broad array of noxious insults the body may sustain, the immune system has 
evolved diverse and complex mechanisms. The first division of the immune system is into innate 
and adaptive immunity. Innate immunity is the first line of defense against an insult, and 
includes epithelial barriers, neutrophils, monocytes, macrophages, dendritic cells (DCs), mast 
cells, natural killer cells, innate lymphoid cells, and complement (1). Epithelial barriers cover the 
body’s surfaces in contact with the external environment, and they provide physical and 
chemical protection from invading microbes. Examples include the skin, lung epithelium, and 
intestinal epithelium. When microbes live on or penetrate epithelia, cells of the innate immune 
system mount an immediate immune response by detecting the microbes non-specifically with 
pattern recognition receptors (PRRs) (1). PRRs detect conserved molecules broadly expressed by 
pathogens (pathogen-associated molecular patterns or PAMPs) or molecules that indicate cell 
damage (danger-associated molecular patterns or DAMPs). For example, Toll-like receptor 4 
(TLR4) is a PRR that detects the PAMP lipopolysaccharide (LPS). LPS is a common component 
of bacterial cell walls, but is not made by mammalian cells. Thus, if an innate immune cell 
2 
detects LPS through TLR4, potentially pathogenic bacteria may be nearby and require 
eradication. Innate immune cells also remove damaged cells and induce tissue repair. Innate 
immunity may resolve infections, but some require a more targeted immune response. A key 
function of innate immunity is the recruitment and activation of adaptive immunity. Adaptive 
immunity is the second line of defense against pathogens, and can be separated into the humoral 
(B cell) and cellular (T cell) responses (1). In a primary infection, the adaptive immune system 
requires approximately a week to activate. Although the adaptive response is much slower than 
the innate response, adaptive immunity is highly specific. B cells and T cells express B cell 
receptors (BCR) and T cell receptors (TCR), respectively. BCRs bind to macromolecules, such 
as lipids, and can be membrane-bound or secreted. TCRs bind to specific peptide antigens and 
are membrane-bound. BCRs and TCRs allow for recognition of a specific pathogen by binding 
to antigens. After binding to cognate antigens, B cells and T cells undergo clonal expansion and 
differentiation into effector cells and memory cells. Effector cells mediate the adaptive immune 
response, and memory cells remain in the host to protect from future responses against the same 
pathogen. 
B cell and T cell precursors develop from common lymphoid progenitor cells in the bone 
marrow (1). B cells also mature in the bone marrow; T cells, however, migrate to and mature in 
the thymus. Several broad lineages of T cells emerge from the thymus: αβ T cells bearing TCRs 
with α and β chains (1), natural killer T cells (NKT) bearing TCRs with an invariant α and 
limited β chain (2), αβ T cells that become intraepithelial lymphocytes (IELs) (3), and γδ T cells 
bearing TCRs with γ and δ chains (1). This thesis focuses on αβ T cells and their role in 
peripheral nervous system (PNS) autoimmunity. 
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1.2 T cell activation and differentiation 
Although TCRs bind peptide antigens, they cannot bind to peptides alone. Rather, they 
bind to peptides bound to major histocompatibility complex (MHC) class I or II on antigen-
presenting cells (APCs). Professional APCs include macrophages, dendritic cells, and B cells; 
other cell types may present antigen in certain contexts. TCRs also require the aid of the co-
receptors CD4 and CD8 to stabilize their interaction with MHC-peptide complexes and initiate 
intracellular signaling. CD4 binds to MHC class II, and CD8 binds to MHC class I; thus, T cells 
expressing CD4 may only interact with cells expressing MHC class II (MHC class II-restricted), 
and CD8+ T cells interact with MHC class I (MHC class I-restricted). T cells that have not yet 
encountered their cognate antigen are called a naïve T cells. Naïve T cells are identified by high 
expression of CD62L (L-selectin), which promotes their trafficking to secondary lymphoid 
organs, and low expression of CD44, which is a cell adhesion molecule that promotes homing to 
and retention in peripheral tissues (1). 
T cell activation requires additional signals beyond binding MHC-peptide complexes. T 
cells must also receive costimulatory signals. APCs express CD80 and CD86 after stimulation 
from microbes or other stimuli (4). CD80 and CD86 bind to CD28 on T cells, which promotes T 
cell activation (4). TCR stimulation without CD80 or CD86 co-stimulation or co-stimulation 
without TCR stimulation do not lead to T cell activation. Since APCs presenting antigens 
without costimulatory molecules are likely to be presenting self-antigens, it is important to 
preclude T cells responses against these antigens. To mitigate reaction to self-peptides, repeated 
TCR stimulation without co-stimulation causes the T cell to undergo programmed cell death 
(apoptosis) or enter a state of anergy. Anergic T cells cannot produce IL-2 and do not proliferate 
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even after TCR stimulation and co-stimulation (1). These mechanisms are part of peripheral 
tolerance, which will be discussed later.  
In addition to TCR and CD28 stimulation, T cells respond to cytokines secreted by APCs 
and other cells in their environment. CD4+ T cells in particular may differentiate into distinct 
subsets (5). IL-12 from an APC promotes the generation of T helper type 1 (Th1) cells; Th1s are 
characterized by expression of the transcription factor T-bet and cytokine IFN-γ, and they fight 
intracellular pathogens. IL-4 promotes Th2 generation; Th2s are characterized by the 
transcription factor GATA-3 and cytokines IL4, IL-5, and IL-13, and they fight parasites. TGF-β 
plus IL-6 promote the generation of Th17s, which are characterized by the transcription factor 
ROR-γt and cytokines IL-17A, IL-17F, and IL-22. Th17s fight extracellular bacteria and fungi. 
Follicular helper T cell (Tfh) differentiation is promoted by IL-6 and IL-21. Tfhs express the 
transcription factor Bcl-6, secrete IL-6 and IL-21, and promote B cell development in germinal 
centers (5). Th9 T cells express PU.1, secrete IL-9 and IL-10, and fight parasites (6, 7). TGF-β 
promotes immunosuppressive induced Tregs (iTregs) that express the transcription factor FoxP3 
and secrete TGF-β. Specific APC subsets and IL-10 promote the generation of 
immunosuppressive Tr1s (8); they do not express FoxP3 and secrete high levels of IL-10. 
Importantly, T helper subsets may express other cytokines; for example, Th1s may secrete 
tumour necrosis factor alpha (TNF-α) and IL-10 (9). 
After TCR stimulation, the intracellular tails of the co-receptor CD3 trigger a complex 
signaling cascade that leads to activation of the T cell through their immunoreceptor tyrosine-
based activation motifs (ITAM) (1). CD3 is expressed on all CD4+ and CD8+ T cells, and is 
composed of γ, δ, two ε chains, and two ζ chains. After binding cognate antigen, T cells become 
“activated” or “antigen-experienced” effector cells. Different markers are sequentially expressed 
5 
on the T cell’s surface. Early activation markers appear within hours of T cell activation. These 
include CD69, which sequesters sphingosine-1-receptor 1 (S1pr1, discussed later). This 
promotes retention of the T cell in its current environment and gives it time to differentiate and 
proliferate. Another early activation marker is CD25, which is the α subunit of the IL-2 receptor. 
IL-2 is an important growth factor for T cells, and CD25 has a very high affinity for IL-2. 
CD40L on T cells binds CD40 on APCs and induces expression of co-stimulatory molecules 
CD80 and CD86. After proliferation and differentiation, activated effector T cells are identified 
by high expression of CD44, low expression of CD62L. 
1.3 T cell development 
As previously mentioned, T cells mature in the thymus. Immature T cells begin 
maturation in the outer cortex of the thymus. They are called double-negative T cells, which 
refers to their lack of CD4 and CD8 expression. The first stage of maturation in the αβ T cell 
lineage is recombination of one TCR β gene locus. If recombination is successful, a new TCR β 
chain is expressed on the T cell’s surface along with a pre-Tα chain. The cell is now a pre-T cell 
with a pre-TCR complex. If the first TCR β recombination fails, recombination begins on the 
other locus. If both fail, the pro-T cell dies. The pre-TCR complex sends intracellular signals that 
promote recombination of the TCR α gene and prevent further recombination of the other TCR β 
locus. This prevention is termed allelic exclusion. Successful rearrangement of the TCR α chain 
leads to expression of a mature αβ TCR and concomitant expression of both CD4 and CD8 co-
receptors. The T cell is now a double-positive T cell. If recombination of the TCR α chain fails, 
the T cell dies. TCR recombination is discussed in greater detail in the following section. 
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1.4 T cell receptor recombination and diversity 
For a T cell to mount an immune response against a pathogen, the T cell must exist prior 
to encountering an antigen of the pathogen and express a TCR specific for that antigen. Thus, the 
host must generate a T cell expressing a TCR that binds to a previously unknown antigen. 
Furthermore, the innumerable diversity of pathogens in nature necessitates a similarly expansive 
repertoire of antigen specificities. The immune system has evolved an elegant solution to the 
conundrum of generating a vast library of αβ TCRs that recognize previously unencountered 
antigens. First, the α and β chain loci in the germline initially contain multiple genes (1). The α 
chain contains approximately 45 variable (V) gene segments, 50 joining (J) gene segments, and 
one constant (C) gene segment. The β chain contains approximately 48 V gene segments, two 
diversity (D) gene segments, two J gene segments, and two C gene segments. When constructing 
an α and β chain, one gene segment of each type is randomly selected and recombined. Thus, 
each unique combination of genes creates unique chains that are then ultimately assembled into a 
mature TCR heterodimer (combinatorial diversity). TCR recombination is performed by the 
lymphoid-specific enzyme VDJ recombinase and additional enzymes involved in DNA double-
strand break repair. The VDJ recombinase contains the recombination activating genes 1 and 2 
(RAG-1, RAG-2). RAG-1 and RAG-2 recognize sequences flanking V, D, and J segments, 
brings the segments close together, and allows for cleavage of intervening DNA. The double-
strand breaks are then repaired by ligases, and a final recombined sequence is formed. In 
additional to combinatorial diversity, which is limited by the number of gene segments in the 
germline, the DNA sequence is further altered at the junctions between segments (junctional 
diversity). Nucleotides at junctions may be randomly removed by exonucleases or added by the 
lymphoid-specific enzyme terminal deoxyribonucleotidyl transferase (TdT). Finally, during 
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recombination, overhanging DNA sequences may be created and filled in. The nucleotides added 
under these conditions are called P-nucleotides. The three junctional regions that contribute most 
to antigen binding and diversity are called complementarity-determining regions (CDRs). CDR3 
contains the greatest amount of diversity. Combinatorial diversity may produce approximately 6 
x 106 unique TCRs, and junctional diversity may theoretically produce up to 1016 TCRs (humans 
are estimated to have 109 unique T cell clones). Thus, massive TCR diversity is generated from 
relatively few genes and among TCRs of similar structure. Given this diversity, an 
immunocompetent host’s T cell repertoire is likely to contain TCRs that bind to antigens of a 
pathogen upon infection. These T cells then expand and mount a specific immune response 
against the pathogen. 
1.5 Tolerance 
1.5.1 Positive Selection 
After expressing a TCR, T cells move to the inner cortex, where they attempt to interact 
with MHC-self-peptide complexes on cortical thymic epithelial cells (cTECs). Most of the 
recombined TCRs fail to bind MHC. Since binding to MHC-peptide complexes on APCs is 
required for T cell function in the periphery, T cells that cannot bind MHC would not be capable 
of mounting an immune response. These T cells do not receive survival signals from their TCRs 
and die by neglect. Approximately 90% of T cells generated die by this mechanism (10). T cells 
with TCRs that successfully bind self-peptide-MHC complexes with low to moderate affinity are 
selected to survive. This process is known as positive selection. TCRs that recognize MHC class 
I maintain CD8 expression and lose CD4 expression (1, 10). TCRs that recognize MHC class II 
preserve CD4 expression and cease CD8 expression. These changes create CD4 or CD8 single-
positive T cells that are MHC class II or MHC class I-restricted, respectively. 
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The stochastic nature of TCR recombination allows the generation of an enormous T cell 
repertoire that can target many pathogens. However, TCR recombination also produces T cells 
that react to host antigens, or self-reactive T cells. Immune response against the body is known 
as autoimmunity. Self-reactive T cells must be eradicated to avoid serious damage to the host. 
1.5.2 Negative Selection 
Lack of immune activation against self-antigens is known as immunological tolerance. 
Tolerance is achieved through two main mechanisms: central tolerance and peripheral tolerance. 
Central tolerance occurs in the medulla of the thymus during T cell development. Peripheral 
tolerance occurs outside the thymus and acts on mature T cells. 
Within the medulla of the thymus, medullary thymic epithelial cells (mTECs), DCs, and 
B cells trigger the deletion of self-reactive T cells in a process called negative selection (1, 11). 
mTECs, DCs, and B cells ectopically express self-antigens in the context of MHC. T cells that 
bind with high affinity or avidity to these self-antigens are forced to undergo apoptosis. 
Importantly, the self-antigens expressed here are expressed throughout the host. Thus, any T 
cells that reacts too strongly to an antigen expressed by a host tissue is eliminated before it can 
escape the thymus and mount an immune response. T cells that bind self-antigens with 
intermediate affinity or avidity may be redirected down the regulatory T cell (Treg) lineage. 
Tregs produced by this mechanism are “natural” or “thymic” Tregs (nTreg). Tregs exert 
immunosuppression, and are part of peripheral tolerance. Notably, negative selection may also 




1.5.3 Autoimmune Regulator 
The ectopic expression of thousands of self-antigens in thymic cells is driven by at least 
two transcription factors: autoimmune regulator (AIRE) (12) and FEZF2 (13). AIRE and FEZF2 
are necessary for negative selection and immune tolerance. AIRE also promotes the negative 
selection of autoreactive T cells in the periphery through extrathymic AIRE-expressing cells 
(eTACs) (14). Deficiency in AIRE or FEZF2 predisposes mice and humans to multi-organ 
autoimmunity. AIRE deficiency in humans, and resultant breakdown of central tolerance, causes 
a disease called autoimmune polyglandular syndrome type 1 (APS-1) or autoimmune 
polyendocrinopathy-candidiasis-ectodermal dystrophy (APECED) (15). Patients with APS-1 
develop autoimmunity against several organs, which frequently begins during childhood and 
teenage years. Affected organs include the parathyroid glands, adrenal glands, thyroid gland, 
pancreas, gonads, liver, stomach, hair, and skin. Interestingly, two unrelated children with APS-1 
also developed autoimmunity against peripheral nerves that resembled chronic inflammatory 
demyelinating polyneuropathy (CIDP) (16). In support of a link between AIRE deficiency and 
CIDP, a strain of non-obese diabetic (NOD) mice harboring a dominant-negative G228W 
mutation in AIRE (NOD.AireGW/+; henceforth referred to as AireGW/+) develop spontaneous 
autoimmune peripheral polyneuropathy (SAPP) that resembles CIDP (17, 18). SAPP in AireGW/+ 
mice shares key features with CIDP, including infiltration of peripheral nerves by CD4+ T cells 
and F4/80+ macrophages (19–21), interferon gamma (IFN-γ) production by CD4+ T cells (22, 
23), and loss of the myelin sheath (demyelination) of peripheral nerves (17, 24). Thus, peripheral 




1.6 Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) 
CIDP is the most common acquired autoimmune peripheral neuropathy, affecting as 
many as 9 in 100,000 people (24). Sometimes considered the chronic form of Guillain-Barré 
Syndrome, CIDP is characterized by chronic, symmetric, relapsing-remitting or progressive 
sensory dysfunction, paresthesia, muscle weakness, impaired balance, and reduced/absent tendon 
reflexes due to autoimmune demyelination of nerves in the PNS (26). Symptoms typically arise 
between ages 30 and 60, but may also occur during childhood between five and 18 years old. 
Inflammation and demyelination in CIDP are multifocal, which causes disease manifestations 
and progression to vary widely among patients. 
Electrodiagnostic testing is central to CIDP diagnosis; nerve conduction is quantified, and 
characteristics of demyelination can be detected. The myelin sheath on peripheral nerves is 
created by the wrapping of Schwann cell plasma membranes around axons of neurons. This 
insulates action potentials traveling along the axons, increasing their velocity and longevity. 
Demyelination leads to reduced conduction velocity, increased distal motor and sensory 
latencies, conduction block, and dispersion of compound muscle action potentials (CMAP) in 
electrodiagnostic testing. 
First-line treatment options for CIDP include glucocorticoids, intravenous 
immunoglobulin (IVIg), and plasma exchange, which utilize nonspecific mechanisms of action 
against CIDP, do not improve disease symptoms in one-third of patients, and do not achieve 
remission or cure in over 70% of patients (27, 28). Thus, current treatments fail to address 
considerable CIDP disease burden. Better understanding of CIDP pathogenesis is an important 
step toward developing new mechanism-based therapies with greater efficacy. 
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Substantial evidence suggests T cells are critical for the development of CIDP (24). First, 
non-obese diabetic (NOD) mice develop spontaneous autoimmune peripheral polyneuropathy 
(SAPP) that resembles CIDP due to defective negative selection of T cells (17, 29). Second, T 
cell-deficient mice fail to develop experimental autoimmune neuritis (EAN), which is an induced 
model of CIDP (30). Third, CD4+ T cells are sufficient to transfer SAPP (17, 29, 31). Finally, T 
cells are present in sural nerve infiltrates of CIDP patients (24). Given the central role of T cells 
in CIDP pathogenesis, I investigated whether T cells were required for SAPP pathogenesis in 
NOD.AireGW/+ mice (Chapter 2). Notably, B cells and macrophages have also been implicated in 
CIDP pathogenesis (24, 32). 
1.7 Interleukin 10 in spontaneous autoimmune peripheral polyneuropathy 
A key function of T cells is the secretion of cytokines (24, 32), and CIDP has been 
associated with increased IFN-γ (22, 23) and tumor necrosis factor alpha (TNF-α) (33). Blockade 
of IFN-γ and TNF-α in SAPP mouse models have revealed disease-promoting roles for these 
cytokines (Bour-Jordan et al., 2005; Zeng et al., 2013; Zhang et al., 2012). Interestingly, 
increased IL-10 expression has also been associated with CIDP (22) (37). However, the role of 
IL-10 in CIDP pathogenesis is unclear.  
IL-10 has multiple anti-inflammatory effects, which include suppressing production of 
pro-inflammatory cytokines, chemokines, and costimulatory molecules in macrophages and 
dendritic cells (38, 39). IL-10 dampens autoimmunity in multiple disease models, including 
rheumatoid arthritis (RA) (40, 41) and multiple sclerosis (MS) (42, 43). Recombinant human IL-
10 is a 17-18 kDa homodimer (38). Its sequence is well conserved across multiple species; for 
example, mouse and human IL-10 have 73% sequence homology. IL-10 binds to and signals 
through IL-10 receptors 1 and 2 (IL-10R1, IL-10R2). IL-10R1 is primarily expressed on 
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hematopoietic cells, although its expression may be induced in other cell types (38). IL-10R1 is 
responsible for the immunosuppressive effects of IL-10, and it signals through janus kinase 1 
(JAK1) and signal transducer and activator of transcription 1, 3, and 5 (STAT1, STAT3, STAT5 
in non-macrophage cells). STAT3 mediates the immunosuppressive effects of IL-10. IL-10R2 is 
constitutively expressed on most cells, and it signals through tyrosine kinase 2 (Tyk2). 
Although IL-10 typically suppresses inflammation, it has also been reported to promote 
immune responses. For example, IL-10 secretion by T helper 2 (Th2) cells promotes 
differentiation and antibody secretion in B cells (44, 45), which is strongly associated with 
inflammation in systemic lupus erythematosus (SLE) (46) and allergy (47). Furthermore, IL-10 
stimulates the expansion and differentiation of effector CD8+ T cells, which boosts anti-tumor 
immunity in mice (48). Thus, while IL-10 is most commonly regarded as an anti-inflammatory 
cytokine, it is a pleiotropic cytokine that can also promote inflammation in certain immune 
contexts. 
IL-10 signaling leads to phosphorylation of STAT3 (pSTAT3) (39). Along with increased 
IL-10, CD4+ T cells from CIDP patients with active disease have higher pSTAT3 (22). 
Separately, pSTAT3 has been shown to induce S1pr1 expression (49). The concurrent roles of 
pSTAT3 in IL-10 signaling and S1pr1 transcriptional induction suggest that IL-10 may 
contribute to S1PR1 expression and S1PR1-dependent lymphocyte migration. However, multiple 





1.8 Sphingosine-1-phosphate receptor 1 (S1PR1) 
S1PR1 is a Gαi-coupled G-protein-coupled receptor (GPCR) important for lymphocyte 
migration (50); furthermore, it has been implicated in SAPP pathogenesis (51). S1PR1 is part of 
a family of five S1PR receptors. S1PR1 binds to its ligand sphingosine-1-phosphate (S1P) with 
picomolar affinity, enabling T cells to follow gradients of S1P (52). S1PR1-dependent migration 
allows T cells to exit the thymus after development, secondary lymphoid organs, and sites of 
inflammation. In lymph nodes, T cell migratory behaviour is driven by a balance between 
retention and egress signals. When naïve T cells first enter lymph nodes, their S1PR1 surface 
expression is very low because high S1P levels in the blood lead to S1PR1 internalization and 
degradation (52). Conversely, expression of the Gi GPCR C-C motif chemokine receptor 7 
(CCR7) on the surface of T cells is high. CCR7 binds C-C motif chemokine ligand 19 and 21 
(CCL19, CCL21) on lymph node stromal cells, which send retention signals to the cell. Thus, 
retention signals outweigh egress signals, leading to retention of the T cells in the node. 
Retention in lymph nodes grants time for T cells to sample antigens presented by local APCs and 
clonal expansion after binding cognate antigen (52). Over time, T cells become re-sensitized to 
S1P through re-expression of surface S1PR1. If T cells do not encounter cognate antigens or 
after clonal expansion is complete, S1PR1 signaling outweighs CCR7 signaling, leading to T cell 
egress from the lymph node. 
Given the efficacy of S1PR1 as a therapeutic target (53, 54), there has been much effort 
in delineating factors controlling its expression. Regulators of S1pr1 expression in T cells 
include micro RNA 155 (miR-155), Forkhead box O1 (Foxo1), Krüppel-like factor 2 (KLF2), G 
protein-coupled receptor kinase-2 (GRK2), CD69, and Dynamin 2. miR-155 downregulates 
S1pr1 by binding the 3’-UTR (55). In the absence of TCR signaling, Foxo1 drives KLF2 
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expression (52, 56), and KLF2 binds and activates the promoter of S1pr1 (52, 57). After TCR 
stimulation, Akt phosphorylates and sequesters Foxo1 in the cytosol, preventing it from binding 
KLF2 and other downstream targets (52, 56). After S1P binds S1PR1, GRK2 phosphorylates and 
down-modulates S1PR1, allowing lymphocytes to escape circulation and enter lymph nodes 
(58). CD69 binds directly to S1PR1, which leads to S1PR1 internalization and degradation (52, 
59, 60). Dynamin 2 is necessary for effective endocytosis and subsequent signaling of S1PR1 
(61). Whether IL-10 also regulates S1pr1 through STAT3, however, is not known. 
 IL-10 and CIDP are correlated, but the effect of IL-10 in CIDP is unclear. Thus, I used 
NOD.AireGW/+ mice deficient in IL-10 to understand its role (Chapter 3). I found that IL-10 
paradoxically promoted SAPP, and that this effect was due to the previously unappreciated 
transcriptional induction of S1pr1 by IL-10 through STAT3. While STAT3 has been reported to 
bind to S1pr1 promoter, a link between IL-10 and S1pr1 transcription was previously unknown. 
My secondary investigations of these mice yielded interesting results that may lead to additional 








CHAPTER 2: T CELLS IN NEUROPATHY 
2.1 Introduction 
Given that T cells are important in EAN and sufficient to transfer SAPP, we sought to 
determine whether they are required for SAPP development in NOD.AireGW/+ mice. To test this, 
we crossed NOD.AireGW/+ mice with TCRα-deficient NOD mice (62). Genetic ablation of the 
TCRα chain prevents immature T cells from interacting with cTECs and they die by neglect. 
Thus, no mature T cells are generated, and the periphery is devoid of T cells. B cells and other 
parts of the immune system are intact. I then monitored SAPP development in T cell-deficient 
AireGW/+ mice. 
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2.2 Materials and Methods 
Mice 
NOD.AireGW/+ mice were generated as previously described (63). NOD.TCRα–/– mice 
were purchased from Jackson Laboratory (62). Mice were housed in a specific-pathogen-free 
(SPF) barrier facility at the University of North Carolina, Chapel Hill. Clinical neuropathy, 
determined by hind limb weakness, and diabetes, determined by presence of glucose in urine, 
were assessed at least once per week as described previously (64). Diabetic mice were treated 
daily with intraperitoneal insulin until used in experiments or euthanasia (due to >20% weight 
loss). Only female mice were utilized due to higher SAPP incidence relative to males (17). 
Sciatic nerves of mice were utilized at 22 weeks of age unless otherwise noted. Due to the rapid 
progression of disease and death following initial symptoms, mice that developed SAPP prior to 
22 weeks of age were harvested at SAPP onset. Experiments complied with the Animal Welfare 











Harvested organs were fixed in 10% buffered formalin for at least 96 hours, washed in 
30% ethanol for 20 minutes, and then stored in 70% ethanol. Organs were embedded in paraffin, 
sectioned, and stained with H&E by the UNC Animal Histopathology Core. Immune infiltration 
was scored while blinded to genotype as previously described (63). For sciatic nerves, scores of 
0, 1, 2, 3, and 4 indicate 0%, 1-25%, 26-50%, 51-75%, and >75% infiltration, respectively. 
Electrophysiology 
Sciatic nerve conduction studies were performed as described (65), using a Teca Synergy 




2.3 Results and Discussion 
 T cell-sufficient AireGW/+ mice developed SAPP between 15 and 25 weeks, whereas T 
cell-deficient AireGW/+ mice did not develop SAPP (Figure 2.1A). T cell-deficient AireGW/+ mice 
were free of SAPP out to 35 weeks of age. At 22 weeks of age, sciatic nerves of T cell-sufficient 
AireGW/+ mice were infiltrated with immune cells, whereas nerves from T cell-deficient mice 
were free of infiltration (Figure 2.1B, C). EMGs of 22-week-old T cell-sufficient AireGW/+ mice 
revealed signs of demyelination, including reduced peak amplitude, reduced conduction velocity, 
and increased action potential duration (Figure 2.1D, E). Conversely, T cell-deficient mice had 
no evidence of demyelination, and were indistinguishable from WT mice (Figure 2.1D, E). 
These data demonstrated that T cells are required for SAPP pathogenesis. Without T cells, 
AireGW/+ mice were free of any signs of disease. These results support the theory that T cells are 
central to CIDP pathogenesis, and suggest focusing on T cell biology in disease may yield 
efficacious therapeutic targets against CIDP. 
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Figure 2.1. T cell deficiency prevents SAPP. AireGW/+ TCRα+/– and AireGW/+ TCRα–/– mice were 
monitored for SAPP. (A) SAPP incidence curves. p-value was calculated using Mantel-Cox log-
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rank test; ****, p < 0.0001. (B) H&E-stained sciatic nerves from 22-wk-old mice (Magnification 
x200). (C) Cumulative sciatic nerve infiltration scores from 22-wk-old mice. p-value was 
calculated using Fisher’s Exact test with Bonferroni’s correction; **, p < 0.01, *** p < 0.001. 
(D) Representative proximal compound muscle action potentials from sciatic nerves of 22-wk-
old mice. (E) Cumulative peak amplitude, conduction velocity, and duration of compound 
muscle action potentials from 22-wk-old mice. p-values were calculated using one-way ANOVA 
with Tukey’s correction for multiple comparisons; *, p < 0.05, ***, p < 0.001, ****p < 0.0001. 







CHAPTER 3: CYTOKINES IN NEUROPATHY1 
3.1 Introduction 
IL-10 is increased in CIDP patients (22), but the functional significance of IL-10 in CIDP 
is unknown. In this study, we found that, like CIDP patients, AireGW/+ mice with SAPP have 
robust induction of IL-10. IL-10 expression was increased in inflamed peripheral nerves and T 
cells isolated from spleens and lymph nodes. To test the role of IL-10 in SAPP, we crossed 
NOD.AireGW/+ mice with NOD.Il10–/– mice to generate IL-10-sufficient and IL-10-deficient 
AireGW/+ mice (66). Unexpectedly, IL-10-deficient AireGW/+ mice were protected from SAPP 
development, suggesting IL-10 is a pathogenic cytokine in SAPP. IL-10 deficiency was 
associated with accumulation of activated CD4+ T cells in the draining lymph nodes and 
decreased PNS infiltration. These findings suggested that impaired T cell egress may underlie 
SAPP protection in IL-10 deficiency. Indeed, IL-10-deficient CD4+ T cells lacked S1pr1 
expression and displayed reduced migration to the S1PR1 ligand sphingosine-1-phosphate (S1P). 
Moreover, IL-10 induced S1PR1 mRNA expression, and IL-10-mediated S1pr1 expression 
required STAT3. Together, these findings illustrate a previously unappreciated role of IL-10 in 
promoting S1PR1-dependent lymphocyte migration and autoimmune destruction of peripheral 
nerves. 
                                                     
1
Originally published in The Journal of Immunology. Smith, C, D. Allard, Y. Wang, J. F. 
Howard, S. A. Montgomery, and M. A. Su. 2017. IL-10 paradoxically promotes autoimmune 
neuropathy through S1PR1-dependent CD4+ T cell migration. J. Immunol. © 2017 The 
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3.2 Materials and Methods 
Mice 
NOD.AireGW/+ mice were generated as previously described (63). NOD.SCID (JAX stock 
#001303), NOD.µMT–/– (JAX stock #004639), and NOD.Il10–/– (JAX stock #004266) mice were 
purchased from The Jackson Laboratory. Mice were housed in a specific-pathogen-free (SPF) 
barrier facility at the University of North Carolina, Chapel Hill. Clinical neuropathy, determined 
by hind limb weakness, and diabetes, determined by presence of glucose in urine, were assessed 
at least once per week as described previously (64). Diabetic mice were treated daily with 
intraperitoneal insulin until used in experiments or euthanasia (due to >20% weight loss). Only 
female mice were utilized due to higher SAPP incidence relative to males (17). Mice were 
utilized at 22 weeks of age unless otherwise noted. Due to the rapid progression of disease and 
death following initial symptoms, mice that developed SAPP prior to 22 weeks of age were 
harvested at SAPP onset. NOD.AireGW/+ Il10+/– or NOD.AireGW/+ Il10–/– mice were used as 
splenocyte donors. Experiments complied with the Animal Welfare Act and the National 
Institutes of Health guidelines for the ethical care and use of animals in biomedical research. 
Immunohistochemistry 
Mouse sciatic nerves were embedded in Optimal Cutting Temperature (OCT) compound, 
frozen at -20 °C for 2 hours, and then stored at -80 °C. Six micron-thick longitudinal sections 
were fixed with cold acetone, blocked with 2.5% goat serum, and then stained with anti-IL-10 
antibody (Biolegend clone JES5-16E3) for 2 hours at room temperature. After washing with PBS 
+ 0.1% Tween, sections were incubated with anti-rat-HRP antibody for 30 minutes at room 
temperature. DAB solution (Vector Laboratories) was applied to the sections as the chromogen. 
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Flow cytometry 
Flow cytometry was performed as previously described (67). Briefly, single-cell 
suspensions were isolated from spleens or lymph nodes by crushing with forceps, or from sciatic 
nerves by mincing and digestion in 2 mg/ml collagenase. Cells were stained with live/dead 
fixable yellow dye (Life Technologies), anti-mouse CD4 (Biolegend clone GK1.5), anti-mouse 
CD44 (eBioscience clone IM7), anti-mouse CD62L (eBioscience clone MEL-14), anti-mouse 
S1PR1 (R&D clone 713412), anti-mouse IFN-γ (eBioscience clone XMG1.2), and anti-mouse 
IL-10 (BD clone JES5-16E3) antibodies. For intracellular cytokine staining, cells were 
stimulated with PMA/ionomycin for 4 hours at 37 ºC 5% CO2, and permeabilized using BD 
Cytofix/Cytoperm according to manufacturer’s instructions. Cells were analyzed on a CyAn 
ADP Analyzer (Beckman Coulter). Data were analyzed using FlowJo X. 
Histology 
Harvested organs were fixed in 10% buffered formalin for at least 96 hours, washed in 
30% ethanol for 20 minutes, and then stored in 70% ethanol. Organs were embedded in paraffin, 
sectioned, and stained with H&E by the UNC Animal Histopathology Core. Immune infiltration 
was scored while blinded to genotype as previously described (63). For sciatic nerves, scores of 
0, 1, 2, 3, and 4 indicate 0%, 1-25%, 26-50%, 51-75%, and >75% infiltration, respectively. 
Colon histology was scored in a blinded fashion by a board-certified veterinary pathologist as 
previously described (68). Briefly, H&E-stained distal colonic sections were scored based on an 
additive histological injury system that included mucosal ulceration, epithelial hyperplasia, and 
lamina propria mononuclear and neutrophil infiltrates. Pancreatic islet infiltration was scored in a 
blinded fashion as previously described (69). Briefly, H&E-stained pancreatic sections were 
scored based on average degree of islet infiltration. 
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Electrophysiology 
Sciatic nerve conduction studies were performed as described (65), using a Teca Synergy 
T2X EMG system. 
Antibody treatment 
Anti–B7-1 Ab (clone 16.10A1) and anti–B7-2 Ab (clone GL1) were generous gifts of 
Greg Szot (UCSF) or purchased from BioXCell. To induce neuropathy, 14-day-old NOD.Il10+/– 
or NOD.Il10–/– mice were treated with 50 µg Ab or isotype controls (2A3 and Armenian Hamster 
IgG) every other day for seven treatments (36, 64). 
Enzyme-linked Immunospot Assay (ELISpot) 
ELISpot assays were performed according to manufacturer’s protocol (BD). One million 
splenocytes or 8 x 105 lymph node cells were cultured alone, with synthetic ovalbumin (323-339) 
(Invivogen), synthetic myelin protein zero (180-199) (Genemed Synthesis), or PMA/ionomycin 
in DMEM + 10% FBS for 17 hours at 37 ºC 5% CO2. Spots were enumerated using the AID 
iSpot Reader. 
Adoptive Transfer 
Adoptive transfer of CD4+ T cells from spleen was performed as previously described 
(17). Tissue culture plates were coated with 1 µg/mL anti-CD3ε (eBioscience clone 145-2C11) 
and 1 µg/mL anti-CD28 (BD Pharmingen clone 37.51) in sterile PBS overnight at 4 ºC. Plates 
were washed gently with sterile PBS. Whole spleen from 22-wk-old NOD.AireGW/+ Il10+/– or 
NOD.AireGW/+ Il10–/– donors were cultured with plate-bound anti-mouse CD3 and anti-mouse 
CD28 in DMEM (Gibco) + 10% FBS (Sigma-Aldrich) for 4 days at 37 ºC 5% CO2. CD4+ T 
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cells were purified from cultures using the Magnisort CD4+ T cell Enrichment Kit (Invitrogen) 
and 1 x 106 CD4+ T cells were transferred to NOD.SCID Il10+/– or NOD.SCID Il10–/– recipients. 
Diabetic mice were excluded as donors. 
FTY720 Treatment 
AireGW/+ mice were treated with DMSO or 1 mg/kg FTY720 (Cayman Chemical). 
FTY720 was first dissolved in DMSO (25g in 1 mL DMSO), aliquoted, and frozen at -20 ºC. 
Mice were given intraperitoneal injections of DMSO or FTY720 dissolved 1:100 in 100 µL 
sterile water on every week day (5 days per week) from 14 weeks of age (before SAPP 
development) until utilization. Mice were harvested when they developed SAPP, or when all 
DMSO-treated controls developed SAPP. 
Chemotaxis Assay 
Chemotaxis was measured using transwell assays as described by (70). Migration of 
lymph node cells was measured using a 24-well transwell plate (Corning Life Sciences) with 6.5 
mm polycarbonate filters and five µm pores. The lower chamber was coated overnight at 4 ºC 
with 600 µl of 100 µg/ml human collagen type IV (Sigma-Aldrich) in 0.5 M acetic acid, washed 
with PBS, and air-dried. Two million cells were resuspended in 100 µl RPMI 1640 medium with 
0.1% fatty acid-free BSA (Sigma-Aldrich), 100 U/ml penicillin G, 2mM L-glutamine, and 25 
mM HEPES buffer. Cells were placed on the Transwell inserts. S1P (20 nM in 600 µL) was 
added in the same medium to the lower chamber. Migration was performed for four hours at 37 
ºC 5% CO2. Migrated cells were counted with a hemocytometer. Migration assays without S1P 
were performed in parallel to assess baseline migration. Net migration to S1P was calculated by 
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subtracting the number of cells that migrated nonspecifically from the number of cells that 
migrated to S1P. 
IL-10 Stimulation and Real Time RT-PCR 
Five hundred thousand cells from fresh sciatic and lumbar lymph nodes of NOD.Il10–/– 
mice were stimulated with recombinant human IL-10 (100 ng/mL from Peprotech), stimulated 
with IL-10 and STA-21 (10 µM from Santa Cruz Biotech), or incubated without stimulation in 
XVIVO 15 + Transferrin serum-free media (Lonza) for 30 minutes at 37 ºC 5% CO2. RNA was 
isolated from cells using the Zymo RNA MicroPrep kit. Superscript II (Invitrogen) reverse 
transcriptase was used to create cDNA. TaqMan universal PCR Master Mix (Applied 
Biosystems) was used for qPCR. Commercially available TaqMan primer-probe sets for IL-10 
and S1Pr1 were used (Applied Biosystems). Cyclophilin A was used as an internal control and 
detected with the primer-probe set reported by (63). Reactions were run on a Quantstudio 6 Flex 
system (Life Technologies) and analyzed as described (63). 
Statistics 
Data were analyzed with Graphpad Prism 6 using one-sample two-tailed Student’s t tests, 
unpaired two-tailed Student’s t tests or one-way ANOVA. The Bonferroni or Tukey corrections 
for multiple comparisons were used when appropriate. Mantel-Cox log-rank tests were used to 
compare survival curves. R (v3.3.1) was used to perform Fisher’s Exact test and false discovery 
rate (FDR) adjustments. p<0.05 was considered significant, unless the threshold was reduced for 
the Bonferroni correction. 
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3.3 Results 
IL-10 promotes SAPP in two mouse models. 
IL-10 mRNA expression was compared by qPCR in whole sciatic nerve from NOD wild-
type (WT) vs. AireGW/+ mice with SAPP (Figure 3.1A). IL-10 mRNA was not detected in WT 
nerves, whereas AireGW/+ nerves expressed abundant IL-10. Additionally, immunohistochemical 
staining for IL-10 protein revealed increased protein expression in AireGW/+ nerves compared to 
WT (Figure 3.1B). Thus, similar to CIDP, SAPP in AireGW/+ mice is associated with increased 
IL-10 expression. 
To determine IL-10’s role in SAPP pathogenesis, we crossed NOD.Il10–/– mice (66) with 
NOD.AireGW/+ mice to generate NOD.AireGW/+ Il10+/– and NOD.AireGW/+ Il10–/– mice. Lack of 
IL-10 protein expression in NOD.AireGW/+ Il10–/– mice was confirmed by intracellular IL-10 
staining and flow cytometry of CD4+ T cells (Figure 3.1C). On the C3H/HeJBir and 129/SvEv 
backgrounds, IL-10 deficient mice are susceptible to colitis, growth retardation, anemia, and 
early death (68, 71, 72). Such findings could potentially prevent our ability to observe SAPP in 
NOD.AireGW/+ mice. However, we did not observe colitis or its associated symptoms in NOD.WT 
Il10–/– or NOD.AireGW/+ Il10–/– mice (Figure 3.6 and data not shown). These results are consistent 
with prior reports that colitis is mild and transient on the NOD background (73), and suggest that 
NOD.AireGW/+ Il10–/– mice can be used to understand the impact of IL-10 on SAPP development. 
Given their utility, NOD.AireGW/+ Il10+/– mice and NOD.AireGW/+ Il10–/– littermates were 
monitored for SAPP for 30 weeks. Consistent with our previous data, 80% of the IL-10-
sufficient AireGW/+ mice developed SAPP by 22 weeks of age (AireGW/+ Il10+/–, Figure 3.1D) (Su 
et al., 2012). Strikingly, compared to IL-10-sufficient AireGW/+ mice, IL-10-deficient AireGW/+ 
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mice had a significant delay in SAPP (AireGW/+ Il10–/–, Figure 3.1D), which suggests that IL-10 
accelerates SAPP development. None of the IL-10-sufficient or deficient Aire WT mice 
developed SAPP during the study (WT Il10+/– or Il10-/–, Figure 3.1D), indicating that IL-10 
deficiency does not impair nerve function. Additionally, extensive cellular immune infiltrate was 
seen in H&E-stained sciatic nerves of IL-10-sufficient AireGW/+ mice, but was absent in IL-10-
deficient AireGW/+ mice (Figure 3.1E, F). Finally, SAPP in IL-10-sufficient AireGW/+ sciatic 
nerves was associated with electrophysiological changes consistent with demyelination, 
including prolonged distal motor latencies, slowed conduction velocity, and increased compound 
muscle action potential (CMAP) duration due to temporal dispersion relative to WT nerves 
(Figure 3.1G, H). Conversely, abnormalities were not detected in sciatic nerves of IL-10-
deficient AireGW/+ mice (Figure 3.1G, H). IL-10-deficiency therefore protects against SAPP 
development, nerve infiltration, and electrophysiological changes in AireGW/+ mice. These 
findings that suggest that IL-10 promotes SAPP were surprising, given IL-10’s well-described 
functions as an immunoregulatory cytokine in a number of autoimmune diseases (38).  
SAPP has been described in multiple mouse models, including NOD mice deficient in 
costimulatory molecules B7-1/2 (64). To determine whether the effect of IL-10 deficiency on 
SAPP was specific only to Aire-deficient mice or generalizable to other SAPP models, we 
treated IL-10-sufficient and IL-10-deficient WT mice with anti-mouse B7-1 and anti-mouse B7-
2 to induce autoimmune peripheral neuropathy (36, 64). By approximately 12 weeks of age, 
100% of the anti-B7-1/2 treated, IL-10-sufficient WT mice had SAPP compared to only 22% of 
IL-10-deficient WT mice (Figure 3.2A). At 12 weeks of age, sciatic nerves of IL-10-sufficient 
WT mice were heavily infiltrated, whereas sciatic nerves of IL-10-deficient WT mice had 
significantly less infiltration (Figure 3.2B, C). These data suggest IL-10’s promotion of 
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autoimmunity against peripheral nerves is not specific to the Aire-deficient model, but is a more 
generalizable feature of SAPP pathogenesis. 
It is unclear whether IL-10’s effect in promoting SAPP reflects a more global, 
generalized role in promoting autoimmunity against all target tissues. In addition to SAPP, 
AireGW/+ mice also develop autoimmune diabetes (17), allowing us to concurrently assess the role 
of IL-10 in SAPP and diabetes in these mice. Although IL-10 deficiency delayed SAPP 
development, lack of IL-10 did not affect autoimmune diabetes development in AireGW/+ mice 
(Figure 3.7). This finding is consistent with previous reports that IL-10 does not alter diabetes 
incidence in NOD.WT mice (66). Thus, IL-10 appears to promote autoimmunity in a tissue-
specific manner. 
IL-10 produced by CD4+ T cells promotes SAPP development. 
Many cell types in the innate and adaptive immune systems produce IL-10 (39). 
Therefore, it is not clear which IL-10-producing cell type is important in promoting SAPP. A key 
source of IL-10 is CD4+ T cells, and CD4+ T cells are sufficient to transfer SAPP in multiple 
models (29, 35, 36). Given the critical role for CD4+ T cells in SAPP, we examined IL-10 
expression in CD4+ T cells from WT and neuropathic AireGW/+ mice. IL-10 expression in CD4+ 
T cells from the spleen and nerve-draining lymph node of neuropathic AireGW/+ mice was 
significantly increased compared to WT mice (Figure 3.3A, B). Furthermore, while CD4+ T 
cells were absent in WT sciatic nerve, >10% of infiltrating CD4+ T cells expressed IL-10 in 
AireGW/+ sciatic nerves. Thus, increased IL-10 expression within CD4+ T cells is associated with 
SAPP development. 
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Given increased CD4+ T cell IL-10 expression with SAPP, we next sought to determine 
whether IL-10 production by CD4+ T cells is sufficient to promote SAPP. Purified AireGW/+ 
CD4+ T cells that were IL-10 sufficient or deficient were transferred to immunodeficient 
NOD.PrkdcSCID/SCID (SCID) (74) recipients that were either IL-10 sufficient or deficient (outlined 
in Figure 3.3C, left). IL-10 sufficient donor CD4+ T cells induced SAPP in IL-10-sufficient and 
deficient recipients 6-7 weeks post-transfer (Figure 3.3C, right). Conversely, IL-10-deficient 
donor CD4+ T cells induced SAPP in IL-10-sufficient and deficient recipients 10 weeks post 
transfer, which was a significant delay relative to IL-10-sufficient donors (Figure 3.3C, right). At 
7 weeks post-transfer, recipients of IL-10-deficient donor CD4+ T cells displayed significantly 
less sciatic nerve infiltration than recipients of IL-10-sufficient donor CD4+ T cells (Figure 
3.3D, E).  These data demonstrate that IL-10 production by CD4+ T cells is sufficient to promote 
SAPP development. 
IL-10-deficient AireGW/+ mice harbor highly activated CD4+ T cells. 
IL-10 has a well-described role in suppressing T cell activation (38). Since IL-10 
unexpectedly promoted SAPP (Figure 3.1 and 3.2), whether IL-10 would suppress or enhance T 
cell activation was not clear. Thus, we characterized CD4+ T cell activation in IL-10-deficient 
AireGW/+ mice that were protected from SAPP. Frequencies of CD4+CD44hiCD62Llo activated T 
cells were compared in the spleens of WT, IL-10-sufficient AireGW/+, and IL-10-deficient 
AireGW/+ mice. IL-10-deficient AireGW/+ mice had significantly higher frequencies of activated 
CD4+ T cells relative to IL-10-sufficient WT mice and AireGW/+ mice (Figure 3.4A, B). We next 
test whether IL-10 would suppress or enhance CD4+ T cell expression of IFN-γ, a cytokine 
critical for SAPP development (35, 36).  While IL-10-deficient AireGW/+ mice had significantly 
greater frequencies and absolute numbers of IFN-γ-producing CD4+ T cells in the spleen 
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compared to WT mice, numbers of IFN-γ-producing CD4+ T cells were not different compared 
to IL-10-sufficient AireGW/+ mice (Figure 3.4C, D). In the draining lymph node, IL-10-deficient 
AireGW/+ mice had greater absolute numbers of IFN-γ-producing CD4+ T cells compared to both 
WT and IL-10-sufficient AireGW/+ mice (Figure 3.4E, F). Thus, despite protecting from SAPP, 
IL-10 deficiency was associated with equivalent or increased CD4+ T cell activation and IFN-γ 
production.  
In addition to suppressing T cell activation, IL-10 also downregulates expansion of self-
antigen specific T cells (75). Since IL-10 unexpectedly promoted SAPP, however, we sought to 
determine how IL-10 deficiency would alter the precursor frequency of PNS-specific T cells. 
Pathogenic CD4+ T cells target the self-antigen myelin protein zero (P0) (17). For this reason, 
we assessed the expansion of P0-specific CD4+ T cells using an ELISpot detecting IFN-γ. One 
million splenocytes from WT, IL-10-sufficient AireGW/+, and IL-10-deficient AireGW/+ mice were 
left unstimulated (Media), stimulated with MHC II-restricted ovalbumin irrelevant peptide, 
stimulated with MHC II-restricted P0 peptide, or stimulated with PMA/ionomycin for a positive 
control (data not shown). IL-10-deficient AireGW/+ splenocytes stimulated with P0 elicited 119 
IFN-γ spots on average, which was significantly higher than WT (11 spots) and trended higher 
than IL-10-sufficient AireGW/+ mice (84 spots) (Figure 3.4G, H). We also tested cells from the 
nerve-draining lymph nodes for response to P0. Similar to spleen, the number of P0-specific T 
cells was significantly higher in IL-10-deficient AireGW/+ lymph nodes (99 spots) relative to WT 
(6 spots) and similar to IL-10-sufficient AireGW/+ mice (111 spots) (Figure 3.4I, J). Thus, IL-10-
deficiency protected from the development of SAPP, but does not decrease the frequency of 
nerve-specific CD4+ T cells in spleen or draining lymph nodes.  
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IL-10 deficiency is associated with enlarged lumbar lymph nodes, impaired lymphocyte 
migration, and reduced S1pr1 expression in CD4+ T cells. 
IL-10 deficiency was associated with minimal immune infiltrate in the sciatic nerves 
(Figure 3.1 and 3.2) and, concurrently, activated T cells in the spleen and lymph nodes (Figure 
3.4). One potential explanation for these disparate findings is that IL-10 is required for T cell 
egress from secondary lymphoid structures. Without IL-10, then, activated T cells may 
accumulate in the lymph nodes rather than migrating into peripheral nerves. Since reduced 
lymphocyte egress is associated with increased lymph node cellularity (76), we first tested 
whether IL-10 deficiency may affect migration by investigating lymph node size in IL-10-
deficient mice. Indeed, the nerve-draining lumbar lymph nodes were enlarged in IL-10-deficient 
AireGW/+ mice relative to WT and IL-10-sufficient AireGW/+ mice (Figure 3.5A). On average, IL-
10-deficient AireGW/+ lumbar lymph nodes had >3-fold more cells than WT lymph nodes and ~3-
fold more cells than IL-10-sufficient AireGW/+ lymph nodes (Figure 3.5B). These findings lend 
support to the hypothesis that IL-10 may accelerate SAPP by promoting migration of T cells out 
of lymph nodes and into nerves.  
T cells exit lymph nodes by expressing S1PR1 on the cell surface and following gradients 
of S1P (50).  To test IL-10’s effects on lymphocyte migration, we measured chemotaxis to S1P 
of lymph node cells from IL-10-sufficient and IL-10-deficient AireGW/+ mice in a transwell assay. 
IL-10-deficient AireGW/+ lymph node cells had significantly reduced net migration to S1P, with a 
>3-fold reduction in migrating cells relative to IL-10-sufficient AireGW/+ mice (Figure 3.6C). 
These findings suggest that IL-10 increases T cell migration to S1P. 
We next sought to determine whether reduced chemotaxis to S1P by IL-10-deficient 
AireGW/+ lymphocytes may be due to reduced S1PR1 expression. To test this, we measured S1pr1 
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mRNA in CD4+ T cells purified from lumbar lymph nodes of IL-10-sufficient and deficient 
AireGW/+ mice. IL-10-deficient AireGW/+ CD4+ T cells expressed 12-fold lower levels of S1pr1 
mRNA relative to IL-10-sufficient AireGW/+ controls (Figure 3.5D). To determine whether 
reduced S1pr1 mRNA correlated with reduced surface protein expression, we measured S1PR1 
surface protein on CD4+ T cells from lumbar lymph nodes of IL-10-sufficient and deficient 
AireGW/+ mice. A significantly lower frequency of CD4+ T cells from lymph nodes of IL-10-
deficient AireGW/+ mice expressed S1PR1 surface protein relative to IL-10-sufficient AireGW/+ 
mice (Figure 3.5E, F). Thus, S1pr1 mRNA and protein were reduced in IL-10-deficient AireGW/+ 
CD4+ T cells. Together, these findings support a model in which IL-10 upregulates S1PR1 on 
CD4+ T cells to enhance their migration into the PNS and promote SAPP development. 
IL-10 induces S1pr1 mRNA in a STAT3-dependent manner. 
How IL-10 upregulates S1pr1 expression is unclear. IL-10 signaling has been shown to 
activate STAT3, and, separately, STAT3 has been shown to upregulate S1PR1 transcription (38, 
49).  Based on these findings, we reasoned that IL-10 may induce S1pr1 in T cells via STAT3 
activation. To test this, we stimulated lymph node cells with recombinant IL-10 in vitro and 
measured relative expression of S1pr1 by qPCR. Lymph node cells from IL-10 deficient (WT 
Il10–/–) mice were used to avoid preexisting induction of S1pr1 by IL-10. We stimulated whole 
lumbar lymph node instead of sorted CD4+ T cells because: 1. the lymph node is predominantly 
composed of T cells, and 2. the additional time required for sorting exposes the cells to an S1P-
low environment, which may lead to S1pr1 resensitization (52, 70). IL-10 induced S1pr1 mRNA 
by ~ 1.8-fold compared to unstimulated cells (Figure 3.5G). Thus, addition of IL-10 is sufficient 
to upregulate S1pr1 in lymph node cells. Notably, STA-21, a STAT3 inhibitor (77), abrogated 
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induction of S1pr1 by IL-10 (Figure 3.5G). Together these data suggest that IL-10 activates 
STAT3 to induce S1pr1 transcription. 
S1pr functional antagonist FTY720 suppresses SAPP development 
S1PR1 expression was reduced in IL-10-deficient AireGW/+ mice (Figure 3.5D-F), 
suggesting that decreased S1PR1 may underlie SAPP protection in IL-10-deficient AireGW/+ 
mice. S1PR1 blockade is being investigated for therapeutic potential in multiple autoimmune 
diseases (53), and is currently in clinical use for the treatment of MS (54), an autoimmune 
disease of the central nervous system (CNS). However, it is unclear whether loss of S1PR1 
prevents SAPP development in AireGW/+ mice. To test this, we blocked S1PR1 activity in 
AireGW/+ mice using the S1PR functional antagonist FTY720 (78). FTY720-treated AireGW/+ 
mice were protected from SAPP development relative to DMSO-treated controls (Figure 3.5H). 
Additionally, on H&E stained sections of sciatic nerves, FTY720 treatment was associated with 
reduced infiltration (Figure 3.5I, J). Thus, S1PR1 plays a key role in promoting SAPP and 




Similar to other autoimmune conditions, such as RA, Sjogren's syndrome, and Grave's 
disease (38, 79–81), IL-10 expression is upregulated in PBMCs of patients with autoimmune 
demyelinating polyneuropathy. Unlike most other autoimmune conditions, however, we report 
here that IL-10 promotes autoimmune peripheral neuropathy rather than suppressing the 
autoimmune response. Moreover, IL-10 deficiency was associated with an accumulation of 
activated CD4+ T cells in the draining lymph nodes and a lack of immune cell infiltration in 
nerves, which suggests a defect in lymphocyte egress from lymph nodes. Indeed, IL-10 
deficiency was associated with reduced S1PR1-mediated lymphocyte migration, and IL-10 was 
sufficient to induce S1pr1 expression. These findings delineate a previously unappreciated 
mechanism by which IL-10 may function to promote autoimmune disease. 
IL-10 has been reported to promote immune responses in other inflammatory contexts. 
For example, IL-10 enhances B cell-mediated immunity (44, 45). However, our data indicate that 
SAPP in Aire-deficient mice can occur independently of B cells. Thus, it is unlikely that IL-10 is 
functioning through B cell activation to promote SAPP. IL-10 also promotes CD8+ T cell-
mediated immunity (82). Although it is possible that this IL-10-dependent mechanism may be 
contributing to SAPP development, our adoptive transfer experiments show that CD8+ T cells 
are dispensable for SAPP transfer since NOD.SCID mice lack CD8+ T cells (74). Instead, our 
data suggest IL-10 induces S1pr1 expression, which promotes CD4+ T cell-mediated migration 
from lymph nodes and autoimmunity against the PNS. 
On the surface, our findings may seem to contradict a recent report that IL-10 protected 
NOD.B7-2–/– mice from SAPP (83). Quan et al., 2015 show that transfer of dendritic cells (DCs) 
pretreated with IL-10 protects from neuropathy. These seemingly contradictory results, however, 
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may not be mutually exclusive. It is possible that IL-10 has distinct effects on different immune 
cell types in SAPP pathogenesis. While IL-10 may have anti-inflammatory effects on DC’s, it 
may also promote CD4+ T cell egress from lymph nodes in SAPP. Overall, however, IL-10 
appears to have a SAPP-accelerating effect, since mice with global IL-10 deficiency are 
protected from SAPP. 
IL-10 protects against inflammation in multiple tissues, such as the colon, joints, and the 
CNS (38). What leads IL-10 to promote autoimmunity against the PNS, and not against other 
organs, is not clear. Peripheral nerves fundamentally differ from other tissues in several ways. 
For instance, a blood-nerve barrier surrounds the PNS, making it an immunologically privileged 
site (84). Furthermore, since nerve tissue and nerve antigens are widely dispersed throughout the 
body, the mechanisms behind nerve inflammation and tolerance may have unique characteristics.  
Also, tertiary lymphoid structures within target organs have been reported to be an important 
source of autoimmune T cells in autoimmune diabetes, MS, SLE, and RA (85), but are not seen 
in the PNS. Thus, differences in location (e.g., tertiary vs. secondary) of critical lymphoid 
structures may be key in accounting for differences between organs. 
CIDP has been observed in several patients with mutations in AIRE (25); however, the 
majority of CIDP patients have no known AIRE deficiency. Thus, an important question is 
whether results obtained in the Aire deficiency model of SAPP can be generalized. We observed 
that IL-10 deficiency protected mice from SAPP not only in the Aire deficiency (AireGW/+) 
model, but also in the Aire-independent, anti-B7-1/2 antibody-induced model. Thus, our findings 
suggest that IL-10’s promotion of SAPP pathogenesis is a common feature of autoimmune 
peripheral neuropathies. Since the Aire-deficient and anti-B7-1/2 antibody models are both on 
the NOD mouse background, it remains possible that IL-10’s promotion of PNS autoimmunity is 
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specific to the NOD background. SAPP models reported to date are all on the NOD background 
(17, 29, 31, 86, 87), so it is not currently possible to test IL-10’s effects on SAPP in other mouse 
strains. 
Our results have multiple clinical implications. We show that IL-10 paradoxically 
promotes SAPP, which suggests increased IL-10 observed in CIDP patients may be a marker of 
disease progression rather than resolution. Furthermore, IL-10 is currently under investigation to 
treat autoimmune and inflammatory diseases, including RA (40, 41), MS (42, 43), and Crohn’s 
disease (88). Our data suggest that IL-10 treatment may have previously unanticipated effects: 
IL-10 therapy may exacerbate disease in CIDP patients and/or unmask PNS autoimmunity in 
susceptible individuals. FTY720 is currently under investigation for clinical use to treat CIDP, 
and our data provide support for its use in treating autoimmune peripheral neuropathy (89). 
Separately, autoimmune peripheral neuropathies are an increasingly common side-effect of 
current treatments and infections. For example, immune checkpoint inhibitors are being 
extensively tested in skin, lung, and kidney cancers, but may cause PNS autoimmunity (90, 91). 
Furthermore, recent Zika virus outbreaks have been strongly linked to an acute autoimmune 
peripheral neuritis that resembles Guillain-Barré syndrome (92, 93). Thus, there is mounting 
need to understand the pathogenesis of autoimmune peripheral neuropathies. This study 
demonstrates a critical role for IL-10 in promoting lymphocyte migration and accelerating PNS 




Figure 3.1. IL-10 deficiency is protective in SAPP. Relative IL-10 mRNA expression (A) and 
immunohistochemical stains of IL-10 (B) (magnification 200x) in sciatic nerves of NOD.WT 
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(WT, n=3) mice and NOD.AireGW/+ (AireGW/+, n=4) mice with SAPP. Scale bar = 100 µm. p-
value was calculated using two-tailed unpaired Student’s t test with Welch’s correction; *, p < 
0.05. (C) Representative flow cytometry plots of live, splenic CD4+ T cells from IL-10-sufficient 
(IL-10+/–) and IL-10-deficient (IL-10–/–) AireGW/+ mice stained for intracellular IL-10. Numbers 
on plots represent frequencies of IL-10-expressing cells. WT Il10+/–, WT Il10–/–, AireGW/+ Il10+/–, 
and AireGW/+ Il10–/– mice were bred and monitored for SAPP. (D) SAPP incidence curves. Arrow 
points to age at which nerves were harvested for histology and EMG. p-value was calculated 
using Mantel-Cox log-rank test of AireGW/+ Il10+/– versus AireGW/+ Il10–/– mice; ***, p < 0.001. 
(E) H&E-stained sciatic nerves from 22-wk-old mice (magnification 200x). Arrow points to 
areas of dense immune cell infiltration. Scale bar = 200µm. (F) Cumulative sciatic nerve 
infiltration scores. p-values were calculated using Fisher’s Exact test with Bonferroni’s 
correction; **, p < 0.01. (G) Representative proximal and distal compound muscle action 
potentials from sciatic nerves of 22-wk-old mice. (H) Cumulative peak amplitude, conduction 
velocity, and duration of compound muscle action potentials from 22-wk-old mice. p-values 
were calculated using one-way ANOVA with Tukey’s correction for multiple comparisons; ***, 




Figure 3.2. IL-10 deficiency is protective in anti-B7-1/anti-B7-2-induced autoimmune 
peripheral polyneuropathy. Anti-B7-1/anti-B7-2 or isotype treated WT or WT Il10–/– mice 
were monitored for SAPP. (A) SAPP incidence curves. p-value was calculated using Mantel-Cox 
log-rank test of anti-B7-1/anti-B7-2- treated WT Il10+/– versus WT Il10–/– mice; **, p < 0.01. 
Arrow points to age at which nerves were harvested for histology in B and C. (B) H&E-stained 
sciatic nerves from 12-week-old mice (magnification 200x). Arrows point to areas of dense 
immune cell infiltration. Scale bar = 60 µm. (C) Cumulative sciatic nerve infiltration scores from 
12-week-old mice. p-value was calculated using Fisher’s Exact test; *, p < 0.05. Each symbol 





Figure 3.3. IL-10 produced by CD4+ T cells promotes SAPP. Spleens, lumbar lymph nodes, 
and sciatic nerves of 22-wk-old WT mice and AireGW/+ mice stained for intracellular IL-10. (A) 
Flow cytometry plots of live CD4+ T cells. Numbers on plots represent frequencies of IL-10-
expressing cells. (B) Cumulative frequencies of CD4+IL-10+ T cells. p-values were calculated 
using two-tailed unpaired Student’s t test with Welch’s correction; **, p < 0.01, ***, p < 0.001, 
****, p < 0.0001. (C) Schematic (left) and SAPP incidence curve (right) of NOD.SCID Il10+/– or 
NOD.SCID Il10–/– recipient mice receiving purified CD4+ T cells adoptively transferred from 
22-wk-old AireGW/+ Il10+/– or AireGW/+ Il10–/– donor mice. p-values were calculated using Mantel-
Cox log-rank test with false discovery rate adjustment for multiple comparisons; *, p < 0.05. 
Arrow points to time when nerves were harvested for histology.  (D) H&E-stained sciatic nerves 
harvested 7 weeks post CD4+ T cell adoptive transfer from the groups described in C. 
(magnification 200x). Scale bar = 98 µm. (E) Cumulative infiltration scores of sciatic nerves 
from recipient mice 7 weeks post transfer. Grouped by donor genotype. p-value was calculated 




Figure 3.4. CD4+ T cells in IL-10-deficient AireGW/+ mice are highly activated. CD4+ T cells 
from spleens and nerve-draining lymph nodes of 22-wk-old WT, AireGW/+ Il10+/+ or +/–, and 
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AireGW/+ Il10–/– mice were analyzed. (A) Flow cytometry plots of live, splenic CD4+ T cells 
stained for CD44 and CD62L. Numbers on plots represent frequencies of CD44hiCD62Llo cells. 
(B) Cumulative frequencies of CD4+CD44hiCD62Llo activated T cells from spleens. p-values 
were calculated using one-way ANOVA with Tukey’s correction for multiple comparisons; 
****, p < 0.0001. (C) Flow cytometry plots of live, splenic CD4+ T cells stained for intracellular 
IFN-γ. Numbers on plots represent frequencies of IFN-γ-expressing cells. (D) Cumulative 
frequencies and numbers of CD4+IFN-γ+ T cells from spleens. p-values were calculated using 
one-way ANOVA with Tukey’s correction for multiple comparisons; *, p < 0.05, **, p < 0.01. 
(E) Flow cytometry plots of live lymph node CD4+ T cells stained for intracellular IFN-γ. 
Numbers on plots represent frequencies of IFN-γ-expressing cells. (F) Cumulative frequencies 
and numbers of CD4+IFN-γ+ T cells from lymph nodes. p-values were calculated using one-way 
ANOVA with Tukey’s correction for multiple comparisons; *, p < 0.05. (G) ELISpot wells 
detecting IFN-γ from P0-stimulated splenocytes. (H) Cumulative numbers of IFN-γ spots from 
media only, ovalbumin-stimulated, or P0-stimulated splenocytes. p-values were calculated using 
two-tailed, unpaired Student’s t test with Welch’s correction and Bonferroni’s correction; *, p < 
0.025, *** p < 0.001. (I) ELISpot wells detecting IFN-γ from P0-stimulated lymph node cells. (J) 
Cumulative numbers of IFN-γ spots from P0-stimulated lymph node cells. p-values were 
calculated using two-tailed, unpaired Student’s t test with Welch’s correction and Bonferroni’s 




Figure 3.5. IL-10 promotes lymphocyte migration through STAT3-dependent S1pr1 
induction. Image (A) and cumulative cell counts (B) of lumbar lymph nodes from 22-wk-old 
WT, AireGW/+ Il10+/+ or +/–, and AireGW/+ Il10–/– mice. p-values were calculated using one-way 
ANOVA with Tukey’s correction for multiple comparisons; *, p < 0.05. (C) Net migration in 
vitro to sphingosine-1-phosphate (S1P) of lymph node cells from 22-wk-old AireGW/+ Il10+/+ or 
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+/– and AireGW/+ Il10–/– mice. p-value was calculated using two-tailed unpaired Student’s t test 
with Welch’s correction; **, p < 0.01. CD4+ T cells from lumbar lymph nodes of 22-wk-old 
AireGW/+ Il10+/+ or +/– and AireGW/+ Il10–/– mice were analyzed for S1PR1 expression. (D) Relative 
S1pr1 mRNA expression. p-value was calculated using two-tailed unpaired Student’s t test with 
Welch’s correction; *, p < 0.05.  (E) Flow cytometry plots of live, lumbar lymph node CD4+ T 
cells stained for extracellular S1PR1. Numbers on plots represent frequencies of S1PR1-
expressing cells. “S1PR1 neg ctrl” indicates negative control for S1PR1 staining. (F) Cumulative 
frequencies of CD4+S1PR1+ T cells. p-value was calculated using two-tailed unpaired Student’s 
t test with Welch’s correction; *, p < 0.05. (G) Relative S1pr1 mRNA expression of lumbar 
lymph node cells from WT Il10–/– mice stimulated with recombinant IL-10 or IL-10 plus STAT3 
inhibitor (STA-21). p-values were calculated using one-sample t test (Unstimulated versus IL-
10) and two-tailed unpaired Student’s t test (IL-10 versus IL-10 + STA-21) with false discovery 
rate adjustment for multiple comparisons; * indicates p < 0.05. DMSO or FTY720-treated 
AireGW/+ mice were monitored for SAPP. (H) SAPP incidence curve. p-value was calculated 
using Mantel-Cox log-rank test; **, p < 0.01. (I) H&E-stained sciatic nerves (magnification 
200x). Scale bar = 98 µm. (J) Cumulative sciatic nerve infiltration scores. p-value was calculated 




Figure 3.6. IL-10-deficient AireGW/+ mice have minimal colitis. Image (A) and cumulative 
histological scores (B) of H&E-stained distal colon from 22-wk-old AireGW/+ Il10+/+ or +/– and 
AireGW/+ Il10–/– mice (magnification 200x). Scale bar = 60 µm. p-value was calculated using 
Fisher’s Exact test. ns indicates no significant difference was observed. Each symbol represents 




Figure 3.7. IL-10 deficiency does not affect diabetes in AireGW/+ mice. AireGW/+ Il10+/– and 
AireGW/+ Il10–/– mice were monitored for diabetes. (A) Diabetes incidence curve. p-value was 
calculated using Mantel-Cox log-rank test; ns indicates no significant difference was observed. 
Pancreatic islet images (B) and cumulative pancreatic islet infiltration scores (C) from 22-wk-old 
mice (magnification 200x). Scale bar = 200 µm. p-value was calculated using Fisher’s Exact test. 









CHAPTER 4: ADDITIONAL EXPERIMENTS ON IL-10-DEFICIENT NOD.AIREGW/+ 
MICE. 
4.1 Introduction 
 While investigating the effects of IL-10 deficiency on SAPP in NOD.AireGW/+ mice, I 
performed various experiments that provide important insight into the immunology of the mice. 
The data are presented in this chapter. 
 
4.2 Materials and methods 
Mice 
NOD.AireGW/+ mice were generated as previously described (63). NOD.Il10–/– (JAX stock 
#004266) mice were purchased from The Jackson Laboratory. C57BL/6 mice were purchased 
from The Jackson Laboratory. BL/6.Il10–/– mice were generous gifts from the R. Balfour Sartor 
lab. Mice were housed in a specific-pathogen-free (SPF) barrier facility at the University of 
North Carolina, Chapel Hill. Clinical neuropathy, determined by hind limb weakness, and 
diabetes, determined by presence of glucose in urine, were assessed at least once per week as 
described previously (64). Diabetic mice were treated daily with intraperitoneal insulin until used 
in experiments or euthanasia (due to >20% weight loss). Only female mice were utilized due to 
higher SAPP incidence relative to males (17). Mice were utilized at 22 weeks of age unless 
otherwise noted. Due to the rapid progression of disease and death following initial symptoms, 
mice that developed SAPP prior to 22 weeks of age were harvested at SAPP onset. 
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NOD.AireGW/+ Il10+/– or NOD.AireGW/+ Il10–/– mice were used as splenocyte donors. Experiments 
complied with the Animal Welfare Act and the National Institutes of Health guidelines for the 
ethical care and use of animals in biomedical research. 
Histology 
Harvested organs were fixed in 10% buffered formalin for at least 96 hours, washed in 
30% ethanol for 20 minutes, and then stored in 70% ethanol. Organs were embedded in paraffin, 
sectioned, and stained with H&E by the UNC Animal Histopathology Core. Immune infiltration 
was scored while blinded to genotype as previously described (63). For salivary glands, lacrimal 
glands, thyroid glands, and eyes, scores of 0, 1, 2, 3, and 4 indicate 0%, 1-25%, 26-50%, 51-
75%, and >75% infiltration, respectively. 
Flow cytometry 
Flow cytometry was performed as previously described (67). Briefly, single-cell 
suspensions were isolated from spleens or lymph nodes by crushing with forceps in DMEM + 
10% FBS, from sciatic nerves by mincing and digestion in 2 mg/ml collagenase + 1% FBS, or 
from pancreatic islet infiltrates by mashing whole pancreas into a 70 μm filters with the butt of a 
5 mL syringe in DMEM + 10% FBS. Cells were stained with live/dead fixable yellow dye (Life 
Technologies), anti-mouse CD21, anti-mouse CD23, anti-mouse IL-17, anti-mouse CXCR3, 
anti-mouse S1PR1 (R&D clone 713412), anti-mouse IFN-γ (eBioscience clone XMG1.2), anti-
mouse FoxP3, anti-mouse CD69, anti-mouse CD25 (clone PC61.5), and anti-mouse IL-10 (BD 
clone JES5-16E3) antibodies. For intracellular cytokine staining, cells were stimulated with 
PMA/ionomycin for 4 hours at 37 ºC 5% CO2, and permeabilized using BD Cytofix/Cytoperm 
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according to manufacturer’s instructions. Cells were analyzed on a CyAn ADP Analyzer 
(Beckman Coulter). Data were analyzed using FlowJo X. 
Real Time RT-PCR 
RNA was isolated from cells using the Qiagen mini prep kit or Zymo RNA MicroPrep 
kit. Superscript II (Invitrogen) reverse transcriptase was used to create cDNA. TaqMan universal 
PCR Master Mix (Applied Biosystems) was used for qPCR. Commercially available TaqMan 
primer-probe sets for IFN-γ, IL-10, Cxcl10, Icam1 and S1Pr1 were used (Applied Biosystems). 
Cyclophilin A was used as an internal control and detected with the primer-probe set reported by 






4.3 CD8+ T cells are more activated and produce more IFN-γ in IL-10-deficient SAPP. 
Summary  
CD8+ cytotoxic T cells may play a role in SAPP, but are not required for disease since 
transfer of CD4+ T cells alone induces SAPP in SCID recipients (17, 36). It is possible that IL-
10 promotes SAPP through CD8+ T cells since IL-10 promotes the growth, differentiation, and 
cytotoxicity of CD8+ T cells (38). Thus, CD8+ T cells were tested for activation markers and 
IFN-γ secretion alongside CD4+ T cells in IL-10-deficient AireGW/+ mice. 
The frequencies of splenic CD8+CD44hiCD62Llo activated CD8 T cells were increased in 
IL-10-deficient AireGW/+ mice relative to IL-10-sufficient controls (Figure 4.1A, B). The numbers 
of IFN-γ-secreting CD8+ T cells in nerve-draining lymph nodes were increased in IL-10-
deficient AireGW/+ mice relative to WT and IL-10-sufficient control mice (Figure 4.2C, D). These 
data suggested that, similarly to CD4+ T cells, CD8+ T cells were more activated in IL-10 
deficiency. In contrast to CD4+ T cells, IFN-γ secretion was not globally increased in CD8+ T 
cells. However, the increased numbers of IFN-γ-secreting CD8+ T cells in nerve-draining lymph 








Figure 4.1. Activated CD8+ T cells are increased in frequency in IL-10-deficient AireGW/+ 
mice relative to IL-10-sufficient counterparts. CD8+ T cells from spleens and nerve-draining 
lymph nodes of 22-wk-old WT, AireGW/+ Il10+/+ or +/–, and AireGW/+ Il10–/– mice were analyzed. 
(A) Representative flow cytometry plots of live, splenic CD8+ T cells stained for CD44 and 
CD62L. Numbers on plots represent frequencies of CD44hiCD62Llo cells. (B) Cumulative 
frequencies of CD8+CD44hiCD62Llo activated T cells and CD8+CD44loCD62Lhi naïve T cells 
from spleens. p-values were calculated using one-way ANOVA with Tukey’s correction for 
multiple comparisons; ****, p < 0.0001.   
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Figure 4.2. Numbers of IFN-γ-expressing CD8+ T cells are increased in the lymph nodes of 
IL-10-deficient AireGW/+ mice. CD8+ T cells from spleens and nerve-draining lymph nodes of 
22-wk-old WT, AireGW/+ Il10+/+ or +/–, and AireGW/+ Il10–/– mice were analyzed. (A) Flow 
cytometry plots of live, splenic CD8+ T cells stained for intracellular IFN-γ. Numbers on plots 
represent frequencies of IFN-γ-expressing cells. (B) Cumulative frequencies and numbers of 
CD8+IFN-γ+ T cells from spleens. p-values were calculated using one-way ANOVA with 
Tukey’s correction for multiple comparisons; *, p < 0.05, **, p < 0.01. (C) Flow cytometry plots 
of live lymph node CD8+ T cells stained for intracellular IFN-γ. Numbers on plots represent 
frequencies of IFN-γ-expressing cells. (D) Cumulative frequencies and numbers of CD8+IFN-γ+ 
T cells from lymph nodes. p-values were calculated using one-way ANOVA with Tukey’s 
correction for multiple comparisons; *, p < 0.05.   
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4.4 Marginal Zone B cells are increased in frequency in IL-10-deficient AireGW/+ mice.  
Summary 
We sought to identify the cellular mechanism by which IL-10 promoted SAPP 
development. IL-10 production by Th2 cells enhances B cell proliferation, differentiation, and 
antibody production (44, 45), and B cells have been shown to promote SAPP in B7-2-deficient 
mice (32). Hence, we tested the possibility that IL-10 promoted SAPP by activating B cells. The 
marginal zone subset of B cells expands (94) and secretes pathogenic autoantibodies in mouse 
models of the autoimmune disease systemic lupus erythematosus (95). Therefore, we 
investigated whether the marginal zone B cell population was expanded in AireGW/+ mice. 
Marginal zone B cells are identified by CD19+CD21hiCD23lo (96). Separately, follicular B cells 
are identified by CD19+CD21intCD23+ (97). IL-10-sufficient AireGW/+ mice (15-22 wk old) had 
significantly increased frequencies of marginal zone B cells compared to WT (15-22 wk old) 
controls (Figure 4.3A, B). This increase in marginal zone B cells was absent in IL-10-deficient 
AireGW/+ mice (22 wk old), suggesting the increase was IL-10 dependent. Concomitantly, splenic 
follicular B cell frequencies were significantly reduced in IL-10-sufficient AireGW/+ mice 
compared to WT controls and IL-10-deficient AireGW/+ mice (Figure 4.3A, B). Increased 
marginal zone B cell and reduced follicular B cell frequencies correlate with SAPP in IL-10-





Figure 4.3. Marginal zone B cells are increased in IL-10-deficient AireGW/+ mice. A. 
Representative flow cytometry plots of live, singlet, CD19+ splenocytes from WT, 
AireGW/+Il10+/- and AireGW/+Il10-/- mice stained for CD21 and CD23 surface expression. Numbers 
represent frequency of CD21+CD23- marginal zone and CD21-CD23+ follicular B cells. B. 
Cumulative frequencies. Each symbol represents an individual mouse. p values were calculated 
using one-way ANOVA. **p<0.01, ***p<0.001.  
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4.5 Protection from SAPP in IL-10-deficient AireGW/+ mice was not mediated by B cells1 
Summary 
IL-10 production by CD4+ T helper 2 (Th2) cells can promote inflammation by 
enhancing B cell proliferation, differentiation, and antibody production (38, 44, 45). We 
therefore sought to test whether IL-10 promotion of SAPP development requires B cells.To test 
whether B cells were pathogenic in SAPP, we crossed AireGW/+ mice with NOD.µMT-/- mice that 
lack mature B cells (98), and monitored SAPP in a female cohort of AireGW/+.µMT+/- and 
AireGW/+.µMT-/- mice. B cell-deficient WT mice (WT.µMT-/-) did not develop SAPP, and served 
as healthy controls (Smith et al., 2017 Figure 3C-3F). SAPP occurred with the same incidence in 
B cell-sufficient and B cell-deficient AireGW/+ mice (Smith et al., 2017 Figure 3C), and sciatic 
nerves exhibited similar infiltration (Smith et al., 2017 Figure 3D). B cell-sufficient and B cell-
deficient AireGW/+ mice displayed similar reductions in peak amplitude, reductions in conduction 
velocity, and increases in action potential duration, indicating equivalent demyelination (Smith et 
al., 2017 Figure 3E, 3F). In summary, B cell deficiency does not protect AireGW/+ mice from 
SAPP, suggesting B cells are not pathogenic. Since B cells do not accelerate SAPP development, 
it is unlikely that B cell enhancement is the mechanism by which IL-10 promotes SAPP. 
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4.6 CD69 expression is not increased in IL-10-deficient NOD.AireGW/+ mice. 
Summary  
IL-10-deficient AireGW/+ mice exhibited delayed SAPP and lymph node lymphocyte 
migration defects due to reduced S1PR1 expression in CD4+ T cells. IL-10 deficiency could 
indirectly lead to reduced S1PR1 expression through increased CD69 expression. CD69 is 
upregulated during the first few hours after T cell activation (1); it binds to S1PR1 and reduces 
its surface expression, suppressing emigration of the T cell from the lymph node (52). 
Furthermore, IL-10 deficiency promotes a pro-inflammatory phenotype in APCs (38) and 
correlates with increased T cell activation (Figure 3.4). Thus, loss of IL-10 could lead to 
increased CD69 expression which could then reduce S1PR1 in T cells. To investigate this 
possibility, I measured CD69 expression in CD4+ T cells of IL-10-sufficient versus IL-10-
deficient AireGW/+ mice. 
 CD69 expression was not different in CD4+ T cells from spleens and lymph nodes of IL-
10-deficient AireGW/+ mice compared to WT or IL-10-sufficient AireGW/+ controls (Figure 4.4). 
These data suggested increased CD69 expression was unlikely to be the cause of reduced S1PR1 
on CD4+ T cells. Although CD4+ T cells were more activated overall, CD69 expression is 
transient. Thus, it is possible that T cell activation is increased, but average CD69 expression is 
unchanged.  
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A   WT     AireGW/+IL-10+/-  AireGW/+IL-10-/- 
   
B   WT     AireGW/+IL-10+/-  AireGW/+IL-10-/- 




Figure 4.4. IL-10 deficiency does not affect CD69 expression in CD4+ T cells. CD4+ T cells 
from spleens and lymph nodes of 22-week-old WT, AireGW/+Il10+/- and AireGW/+Il10-/- were 
stained for CD69 expression using flow cytometry. A. Representative plots of CD4+ T cells 
from spleens. B. Representative plots of CD8+ T cells from lymph nodes. C. Cumulative 
frequencies of CD4+CD69+ T cells from spleens and lymph nodes. p values were calculated 
using one-way ANOVA and Tukey’s correction for multiple comparisons. All comparisons were 
not significant.  
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4.7 S1pr1 mRNA is reduced in IL-10-deficient B6 mice. 
Summary  
IL-10 deficiency causes reduced T cell migration in NOD.AireGW/+ mice due to reduced 
S1pr1 expression in CD4+ T cells (Figure 3.5). IL-10’s induction of S1pr1 may be restricted to 
the NOD mouse background or generalizable to other backgrounds. To determine whether the 
finding is generalizable, I tested S1pr1 mRNA in purified CD4+ T cells from lumbar lymph 
nodes of IL-10-sufficient and IL-10-deficient B6 mice. 
CD4+ T cells from B6.Il10–/– mice expressed significantly less S1pr1 mRNA compared 
to B6 WT mice (Figure 4.5). These data suggest the association between IL-10 deficiency and 
reduced S1pr1 expression is generalizable to other mouse backgrounds. The difference between 
IL-10-sufficient and IL-10-deficient NOD mice is much larger than the same comparison in B6 
mice (~12-fold in NOD versus 1.5-fold in B6). This difference may be due to the systemic 
autoimmunity in NOD mice, which creates an inflammatory milieu that boosts IL-10-secretion 




Figure 4.5. IL-10-deficient B6 mice have reduced S1pr1 mRNA in CD4+ T cells from 
lumbar lymph nodes. RNA was isolated from purified CD4+ T cells from lumbar lymph nodes 
of 12-week-old B6 female mice. S1pr1 mRNA was measured using qPCR with cyclophilin A as 
the control. Student’s t test. *p < 0.05. 
  
64 
4.8 IL-10 deficiency does not affect autoimmune infiltration of organs beyond peripheral 
nerves. 
Summary  
APS-1 patients develop autoimmunity against various organs; endocrine organs are most 
frequently affected (15). Similarly, Aire-deficient NOD mice develop spontaneous autoimmunity 
against some of the same tissues (63). To assess whether IL-10 deficiency affects autoimmunity 
in other tissues, I measured tissue infiltration in the eye, thyroid gland, salivary gland, lacrimal 
gland, pancreatic islets, and distal colon. 
 Histological infiltration scores in the organs tested were not significantly different in IL-
10-deficient AireGW/+ of mice versus IL-10-sufficient counterparts (Figures 3.6, 3.7, and 4.6). 
These data suggested IL-10 deficiency does not affect autoimmunity in organs beyond the PNS. 
Thyroid gland infiltration trended towards reduction with a near-significant p value (p = 





Figure 4.6. Autoimmune manifestations beyond SAPP are not significantly affected by IL-
10 deficiency in AireGW/+ mice. Salivary glands (sialoadenitis), eyes (chorioretinitis), lacrimal 
glands (dacryoadenitis), and thyroid glands (thyroiditis) were harvested from 22-week-old 
AireGW/+Il10+/+ or +/–- and AireGW/+Il10–/– mice. p values were calculated using Student’s t test. All 
p values were greater than 0.05 and therefore not significant.  
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4.9 IL-10 is induced in regulatory T cells and IFN-γ-expressing CD4+ T cells in SAPP. 
Summary 
Given that CD4+ T cells are sufficient to transfer SAPP (17, 29, 64), IL-10 was induced 
in CD4+ T cells in AireGW/+ mice (Figure 3.1B, C), and IL-10 produced by CD4+ T cells 
promoted SAPP (Figure 3.3), we further characterized the CD4+ T cell subsets expressing IL-10. 
FoxP3+ Tregs suppress T cells and APCs through production of IL-10 (39). IL-10 expression in 
CD4+CD25+FoxP3+ Tregs from the spleen, lumbar lymph node, and sciatic nerve infiltrates in 
neuropathic AireGW/+ mice was significantly increased compared to WT mice (Figure 4.7D, E). 
One would presume that the IL-10 produced by FoxP3 Tregs is anti-inflammatory since Tregs 
are immunosuppressive and they suppress SAPP development (unpublished data). However, 
given that IL-10 overall promotes SAPP (Chapter 3), it is possible that Treg IL-10 also 
contributes to S1pr1-mediated egress of nerve-reactive effector T cells. Further studies may 









We also detected CD4+CD25-FoxP3- T cells that produced both IL-10 and IFN-γ. IL-10 
and IFN-γ double-positive Th1 cells were significantly increased in spleen, lumbar lymph node, 
and sciatic nerve infiltrates in neuropathic AireGW/+ mice compared to WT mice (Figure 4.8F, G). 
Th1 cells that coexpress IL-10 are thought to be mediating their own immunosuppression (9). 
Additionally, it is possible that these cells contain Tr1 cells, which are FoxP3 negative 
immunosuppressive cells (99). However, results from Chapter 3 suggest these T cells may be 
promoting their egress from lymph nodes and subsequently promoting SAPP. Thus, either an 
immunosuppressive subset is exhibiting immune-activating properties, or this subset is 
proinflammatory despite expressing IL-10. In summary, IL-10 is induced in multiple CD4+ T 
cell subsets in SAPP, and the individual effects of IL-10 produced by these subsets remain to be 







Figure 4.7. IL-10 production by FoxP3 Tregs is increased in SAPP. CD4+CD25+FoxP3+ 
Tregs from spleen, lumbar lymph nodes, and sciatic nerves of WT and AireGW/+ mice were 
stained for intracellular IL-10 using flow cytometry. A. Representative flow cytometry plots. 
Numbers on plots represent frequency of IL-10-expressing cells. B. Cumulative frequencies of 
IL-10 expressing CD4+CD25+FoxP3+ Tregs. p values calculated using t test. *** p < 0.001, * p 
























Figure 4.8. IFN-γ-IL-10-double-producing effector T cells are increased in frequency in 
AireGW/+ mice with SAPP. A. Gating strategy for CD4+CD25-FoxP3-IFN-γ+IL-10+ effector T 
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cells. Gating sequence proceeds from left-to-right. CD4+CD25-FoxP3- effector T cells from 
spleen, lumbar lymph nodes, and sciatic nerves of WT and AireGW/+ mice were stained for 
intracellular IFN-γ and IL-10 using flow cytometry. B. Representative flow cytometry plots. 
Numbers on plots represent frequency of IL-10-expressing cells. C. Cumulative frequencies of 
CD4+CD25-FoxP3-IFN-γ+IL-10+ effector T cells. CD4+CD25-FoxP3-IFN-γ+IL-10+ effector T 
cells were identified in lumbar lymph nodes and pancreatic lymph nodes of WT and AireGW/+ 
mice. D. Representative flow cytometry plots. E. Cumulative frequencies of CD4+CD25-FoxP3-
IFN-γ+IL-10+ effector T cells. CD4+CD25-FoxP3-IFN-γ+IL-10+ effector T cells were 
identified in sciatic nerves and pancreatic islets AireGW/+ mice. F. Representative flow cytometry 
plots. G. Cumulative frequencies of CD4+CD25-FoxP3-IFN-γ+IL-10+ effector T cells. p values 
calculated using t test. **** p < 0.0001, ** p < 0.01, N.D. none detected.  
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4.10 Th17 cells are induced and recruited in IL-10-deficient SAPP. 
Summary  
To characterize SAPP in the context of IL-10 deficiency, I stained nerve infiltrates for 
IFN-γ in CD4+ and CD8+ T cells using flow cytometry. Approximately 40% of CD4+ T cells in 
infiltrated nerves of IL-10-deficient AireGW/+ mice expressed IFN-γ after stimulation (Fig 4.9A), 
which is similar to published results (17). As a negative control, I also stained for IL-17 in T 
cells. IL-17 is a pro-inflammatory cytokine that promotes EAE (100) and EAN (101); however, 
Th17 cells are not present in the infiltrated nerves of AireGW/+ with SAPP (17). Thus, I expected 
to see minimal IL-17 expression in nerve infiltrates of IL-10-deficient AireGW/+ mice. In contrast 
to expectation, 12 to 14 percent of CD4+ T cells in IL-10-deficient AireGW/+ sciatic nerves 
expressed IL-17 (Figure 4.9A). Furthermore, one to four percent of CD4+ T cells co-expressed 
IFN-γ and IL-17. Expansion of Th17 cells in IL-10 deficiency is likely a result of the lack of 
suppression of Th17 differentiation in the absence of IL-10 (102). Further work is needed to 
determine whether the Th17 T cells are affecting SAPP, or whether their involvement is simply 
an epiphenomenon. Around 90% of CD8+ T cells produced IFN-γ and around 1% produced IL-
















Figure 4.9. Th17 cells are present in infiltrated nerves of IL-10-deficient AireGW/+ mice with 
SAPP. Sciatic nerves from >30-week-old AireGW/+Il10-/- mice with SAPP were digested, 
stimulated with PMA/ionomycin, and stained for CD4 (A), CD8 (B), intracellular IFN-γ and 
intracellular IL-17A. Numbers represent frequencies of cytokine-expressing cells. Each row is an 
individual mouse. All plots are gated on live singlets, and the third column is gated on CD4 (A) 
or CD8 (B). 
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4.11 CXCR3 expression is unchanged in IL-10-deficient NOD.AireGW/+ mice. 
Summary 
SAPP may be delayed in IL-10-deficient AireGW/+ mice due to reduced T cell migration 
from the peripheral blood and into peripheral nerves. C-X-C motif chemokine ligand 10 
(CXCL10) is upregulated in nerves with SAPP (36). CXCR3, which is expressed on Th1 cells, 
binds to CXCL10. CXCR3 may promote T cell infiltration of peripheral nerves through 
CXCL10. Thus, reduced CXCR3 expression could lead to reduced peripheral nerve infiltration 
and delayed SAPP in IL-10-deficient AireGW/+ mice. To assess CXCR3 expression, I used flow 
cytometry on CD4+ and CD8+ splenic T cells from IL-10-sufficient versus IL-10-deficient mice. 
CXCR3 expression was not different in CD4+ and CD8+ T cells from the spleens of IL-
10-deficient AireGW/+ mice compared to IL-10-sufficient controls (Figure 4.10). Preliminary data 
also show CXCR3 expression did not differ in the lymph nodes of these mice (data not shown). 
These data suggest IL-10 deficiency did not affect CXCR3 expression in T cells. Thus, it is 
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Figure 4.10. IL-10-deficiency does not affect CXCR3 expression in CD4+CD62L- and 
CD8+CD62L- T cells. T cells from splenocytes of 22-week-old WT, AireGW/+Il10+/- and 
AireGW/+Il10-/- were stained for CD62L and CXCR3 expression using flow cytometry. A. 
Representative plots of CD4+ T cells. B. Representative plots of CD8+ T cells. C. Cumulative 
frequencies of CD4+CD62L- and CD8+CD62L- T cells expressing CXCR3. p values were 
calculated using one-way ANOVA and Tukey’s correction for multiple comparisons. All 
comparisons were not significant.  
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4.12 Optimization of P0 TCR transgenic splenocyte transfer 
Summary 
 NOD.P0 TCR transgenic mice do not develop SAPP, but their splenocytes can induce 
SAPP in SCID recipients after in vitro anti-CD3/anti-CD28 stimulation or Treg depletion (103). 
To use these mice as an additional SAPP model, I transferred varying numbers of splenocytes to 
SCID recipients. 
 Transfers of 107, 106, and 104 splenocytes led to death of the recipients before SAPP 
development. Transfers of 105 and 103 splenocytes caused SAPP at 4 to 5 weeks post transfer 
(Figure 4.11). These transfers can be used to induce SAPP in large numbers of recipients using a 







Figure 4.11. NOD.P0 TCR Transgenic splenocytes induce neuropathy in NOD.Scid 
recipients. Splenocytes from NOD.P0 TCR Transgenic mice were stimulated for four days in 
vitro with plate-bound anti-CD3/anti-CD28. One thousand to Ten million stimulated splenocytes 
were adoptively transferred to Scid recipients. A. Percent survival for recipients of P0 TCR 








CHAPTER 5: DISCUSSION 
CIDP is a chronic autoimmune disease marked by the targeting and destruction of 
peripheral nerve myelin. Mouse models of CIDP have demonstrated critical roles for T cells and 
their cytokines in pathogenesis. My research has found that in NOD.AireGW/+ mice: T cells are 
required for SAPP development (Chapter 2), and IL-10 produced by CD4+ T cells promotes 
SAPP through induction of S1pr1 and promotion of T cell migration (Chapter 3). My findings 
regarding IL-10 suggest that the increased IL-10 expression observed in CIDP patients may not 
be immunosuppressive. Instead, increased IL-10 may be a marker of inflammation and disease 
progression. In regards to CIDP therapy, my data suggest IL-10-based therapies may exacerbate 
or induce CIDP in susceptible patients. My data also suggest blocking or inhibiting IL-10 may 
alleviate autoimmunity in CIDP; however, this is highly inadvisable given IL-10’s central role in 
general immunosuppression. Even if IL-10 blockade reduced CIDP disease activity, it may 
provoke autoimmunity or inflammation in other contexts. Notably, colitis could be induced (68). 
Modulation of IL-10 expression or signaling would have to specifically target peripheral nerve 
autoimmunity while preserving expression elsewhere. 
Another strategy would be to inhibit T cell emigration from lymph nodes, which would 
be downstream of IL-10’s disease-promoting effect. FTY720 has been tested in a CIDP clinical 
trial; however the trial was ended due to futility (89). There are a few reasons why this trial of 
FTY720 may have failed. First, given that FTY720 reduced SAPP in NOD.AireGW/+ mice when 
given before SAPP onset, it is possible that migration blockade is only effective when initiated 
before nerves become infiltrated. Second, the patients tested continued their normal treatments 
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(IVIg, etc.), so perhaps FTY720 alone is effective but it cannot provide benefit in addition to 
current treatment. Third, the patients in the study experienced less disease relapse than the 
researchers expected. Therefore, perhaps there was not enough disease activity to see an effect of 
FTY720. Given these caveats, blockade of lymphocyte migration may still be a viable treatment 
option for CIDP. S1PR1-blocking drugs beyond FTY720 may also have efficacy against CIDP 
(104). 
My findings in Chapters 2 through 4 give rise to further questions about SAPP in 
AireGW/+ mice and CIDP pathogenesis. 
5.1 Which IL-10-producing CD4+ T cell subset is responsible for promoting SAPP? 
In Chapter 3, I demonstrate that IL-10 promotes SAPP in NOD.AireGW/+ mice, and that 
IL-10 produced by CD4+ T cells is sufficient to promote SAPP in the transfer model of disease. 
However, the specific CD4+ T cell subset or subsets that is or are promoting SAPP remains 
unknown. A multitude of CD4+ T cell subsets can produce IL-10, including Th1, Th2, Th9, 
Th17, FoxP3+ nTreg, FoxP3+ iTreg, and Tr1 (7, 9, 105). Several possibilities arise from this 
knowledge: a T effector subset produces pathogenic IL-10, an ordinarily immunosuppressive T 
cell subset is instead immune-activating in SAPP and produces pathogenic IL-10, an 
immunosuppressive T cell subset dampens autoimmunity except for production of pathogenic 
IL-10, or some combination of the three.  
5.1.1 Pathogenic IL-10 is produced by a T effector subset 
T effectors typically promote inflammation and immune responses. Different immune 
responses, and consequently autoimmune diseases, are often characterized by specific T effector 
subsets. SAPP pathogenesis is marked by significant expansion of Th1 T cells (17), and Th1-
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derived IFN-γ is required for SAPP (36). Conversely, Th2 and Th17 subsets exist in AireGW/+ 
mice at low frequencies, do not expand with disease, and do not infiltrate nerves (17). Th9s are 
also absent in mice with SAPP (data not shown). Additional evidence against a role for Th2s in 
SAPP is that B cells, the targets of Th2-derived IL-10, do not contribute to SAPP pathogenesis 
(Chapter 4.5). Thus, these data suggest Th2, Th9, and Th17 subsets are unlikely candidates for 
promotion of SAPP. The increase in IL-10-producing Th1s in SAPP makes these cells strong 
candidates for SAPP promotion (Figure 4.6). This is also logical conceptually; the IFN-γ they 
produce is required for disease, and the IL-10 they produce may promote their escape from 
lymph nodes and subsequent infiltration of peripheral nerves. Whether Th1s producing IL-10 
expand or whether pre-existing Th1s upregulate IL-10 in SAPP is an additional question. The 
latter seems more likely since IL-10 suppresses proliferation (38) and purified CD4+CD25-IL-
10-GFP+ T cells did not proliferate after 4 days of stimulation in vitro with plate-bound anti-
CD3 and anti-CD28 (observation after I performed this experiment). 
To determine whether IL-10-producing Th1s promote SAPP, the adoptive transfer system 
could be used. IL-10+ Th1s could be purified and transferred to SCID recipients. As shown in 
(Figure 4.8A, B), CD4+ T cells that produce IFN-γ and IL-10 predominantly lack CD25 surface 
expression. Using NOD.AireGW/+ or NOD.P0 TCR transgenic mice expressing an enhanced green 
fluorescent protein (eGFP) reporter under IL-10, the cells can be purified with FACS up to 
around 70% purity (data not shown). The cells could be cultured in vitro with anti-CD3/anti-
CD28 or transferred without manipulation. Recipients would be monitored for SAPP 
development. EMG would confirm the present of demyelination and decreased nerve function. 
Histology of sciatic nerves would be used to visualize global infiltration. Flow cytometry would 
characterize nerve-infiltrating T cells and T cells in draining lymph nodes. One caveat of this 
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experiment is whether T cells still express IL-10 post transfer. The lymphopenic environment in 
SCID recipients could change their phenotype. Thus, it would be important to assess what 
frequency and number of T cells maintain IL-10 expression post-transfer, if any. If recipient 
mice develop SAPP, but transferred cells do not express IL-10, then IL-10 may have an early 
role in promoting infiltration or may not have a role. If recipient mice do not develop SAPP, then 
IL-10-producing Th1s may not be sufficient to induce SAPP. The next step would be to co-
transfer IL-10-producing Th1s with naïve IL-10-deficient CD4+ T cells. Controls for this 
experiment would be a transfer of naïve IL-10-sufficient CD4+ T cells alone and naïve IL-10-
deficient CD4+ T cells alone. Naïve IL-10-sufficient CD4+ T cells would be the positive control 
for SAPP incidence. Naïve IL-10-deficient CD4+ T cells should induce SAPP with delayed 
incidence (Figure 3.3). If IL-10-producing Th1s promote SAPP, then co-transferring them with 
IL-10-deficient CD4+ T cells should accelerate SAPP incidence relative to IL-10-deficient CD4+ 
T cells alone and possibly be indistinguishable from IL-10-sufficient CD4+ T cells alone. Ratios 
and numbers of cells in co-transfers may require optimization. Alternative ways to assign a 
function to IL-10-producing Th1s is to do proliferation assays or suppression assays using co-
cultures with fluorescently-labeled, IL-10-deficient CD4+ T cells. Such studies could find that 
IL-10-producing CD4+ T cells paradoxically promote proliferation or paradoxically lack 
immunosuppressive effects on IL-10-deficient CD4+ T cells. Such functions would be separate 
from the role of IL-10 in promoting migration, but may also be true. 
5.1.2 Pathogenic IL-10 is produced by a T regulatory subset. 
Immunosuppressive T cell subsets can produce IL-10, and IL-10 is thought to be 
immunosuppressive in this context. Furthermore, IL-10 is the primary mechanism of 
immunosuppression for iTregs and Tr1s. However, the fact that IL-10’s net effect is promotion 
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of SAPP suggests IL-10 produced by regulatory T cell subsets may also promote SAPP. 
Preliminary studies suggest Tregs are immunosuppressive in SAPP. First, depletion of Tregs 
with anti-CD25 antibody exacerbates SAPP in male AireGW/+ mice (performed by Anil 
Nagavalli, data not shown). Second, FoxP3+ Treg transfer protects from SAPP (99 and 
performed by Annie Wang, data not shown). These data suggest it is unlikely that IL-10 
produced by Tregs promotes SAPP since Tregs suppress SAPP overall. However, it remains 
possible that IL-10-negative FoxP3+ Tregs may suppress SAPP, whereas IL-10-expressing 
FoxP3+ Tregs promote SAPP. If IL-10 produced by regulatory T cell subsets promotes SAPP, 
then this effect is a paradoxical component of the overall immunosuppressive role of these cells. 
A related question is whether IL-10 is required for immunosuppression in these Treg subsets. 
Similarly to IL-10-producing Th1s, co-transfer experiments and suppression assays may answer 
these questions. Naïve IL-10-deficient CD4+ T cells could be co-transferred with IL-10-GFP 
positive Tregs or IL-10-deficient Tregs versus naïve IL-10-deficient CD4s alone to determine 
whether IL-10 produced by Tregs can promote SAPP. If recipients of IL-10-expressing Tregs 
develop SAPP faster than naïve IL-10-deficient CD4s alone, then IL-10 may promote SAPP 
even when expressed by Tregs. If recipients of IL-10-expressing Tregs develop SAPP at the 
same rate as naïve IL-10-deficient CD4s alone, then either Tregs have no role in SAPP in this 
system or SAPP-promotion by IL-10 may be balanced with SAPP suppression by the Treg 
overall. If recipients of IL-10-expressing Tregs develop SAPP slower than naïve IL-10-deficient 
CD4s alone, then SAPP incidence must be compared to IL-10-deficient Tregs. If IL-10-
expressing Tregs permit faster SAPP than IL-10-deficient Tregs, then IL-10 in Tregs is 
pathogenic. If IL-10-expressing Tregs permit SAPP at the same rate as IL-10-deficient Tregs and 
both are slower than naïve IL-10-deficient CD4s alone, then Tregs protect from SAPP in an IL-
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10-independent manner. If SAPP is slower in recipients of IL-10-expressing Tregs relative to IL-
10-deficient Tregs, then IL-10 in Tregs is protective. Whether IL-10-expression is maintained in 
IL-10-GFP-positive Tregs after transfer is a caveat. 
5.2 Does IL-10 therapy cause or accelerate neuropathy? 
My data in Chapter 3 suggest IL-10 promotes SAPP. This corroborates another story 
where IL-10 overexpression in peripheral nerves induces spontaneous autoimmune neuropathy 
(107). The mechanism of IL-10’s disease promotion in (107) is different; they propose that IL-10 
recruits macrophages that kill Schwann cells through Fas-FasL interactions. They also see very 
few T cells infiltrating nerves. Despite these differences, both suggest IL-10 is an effector in 
SAPP. Whether IL-10 administration in NOD mice can induce or accelerate SAPP is not known. 
NOD mice could be injected with recombinant mouse IL-10 to assess whether SAPP occurs. 
NOD.AireGW/+ mice could be injected with IL-10 to assess whether SAPP occurs earlier or with 
greater severity. Treatment regimens may have to be optimized. IL-10 has a short half-life (108) 
and may not be adequately circulated after injection. Since CD4+ T cell production of IL-10 is 
sufficient to promote SAPP, it is possible that IL-10 must exert its effects specifically in the T 
cell niche of the lymph node (paracortex) in an autocrine and paracrine fashion. Thus, systemic 
delivery of IL-10 may have different effects. These studies may have clinical implications since 





5.3 Is SAPP protection in IL-10-deficient NOD.AireGW/+ mice due to differential gene 
expression beyond S1pr1? 
IL-10 is a pleiotropic cytokine, and dysregulation or loss of IL-10 function changes the 
phenotype of immune cells and typically exacerbates disease (38, 68, 109, 110). In addition to 
reduced T cell migration (Chapter 3), IL-10-deficient NOD.AireGW/+ mice exhibit increased 
frequencies of Th17 cells (Figure 4.9). Thus, it is likely that genes beyond S1pr1 are 
differentially expressed in NOD.AireGW/+ mice. To screen for other gene expression changes that 
may affect SAPP pathogenesis, RNA sequencing of IL-10-sufficient versus IL-10-deficient 
CD4+ T cells from lumbar lymph nodes could be performed. Any immune-related genes with 
significantly different expression could be validated by qPCR and further tested for effects on 
SAPP. 
5.4 Why does IL-10 only promote PNS autoimmunity in NOD.AireGW/+ mice? 
 Interestingly, IL-10 deficiency protects against PNS autoimmunity, but it does not have a 
statistically significant difference in infiltration scores in the eye, thyroid, salivary glands, 
lacrimal glands, or islet beta cells (Figures 3.7 and 4.6). Infiltration scores in thyroid glands 
trended towards reduced infiltration in IL-10-deficient AireGW/+ mice relative to IL-10-sufficient 
counterparts, and the p value was almost significant (p = 0.05303) (Figure 4.6). These data 
suggest IL-10 may also promote autoimmune thyroiditis. Why IL-10 promotes autoimmunity in 
the PNS, but not other tissues, is unknown. One possible explanation is that expansion of an IL-
10-producing cell is specific to PNS autoimmunity. Indeed, Th1s that also produce IL-10 are 
expanded in infiltrated nerves and nerve draining lymph nodes, but not infiltrated islets and 
pancreatic lymph nodes (Figure 4.8D-G). If these Th1s are found to promote SAPP, they may be 
the mechanism by which IL-10 promotes migration of PNS-reactive T cells without affecting 
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other organs. Another possibility is that IL-10 selectively upregulates chemokines in peripheral 
nerves that recruit pathogenic effectors. 
 Many questions remain in the wake of my findings and about CIDP pathogenesis in 
general. Current treatment options are not sufficient to remedy disease in the majority of patients. 
Further study is required to discover new therapeutic targets, and mouse models of disease will 
continue to provide vital insight. 
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5.5 Summary of IL-10’s function in the intestine and peripheral nerves. 
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Figure 5.1. Graphical abstract of IL-10 function in the intestine versus peripheral nerves. 
Summary of the role of IL-10 in inflammation in the intestine (A) and peripheral nerves (B). In 
the intestine, IL-10 secreted by Treg and Tr1 cells promotes a resting/tolerigenic phenotype in 
APCs by downregulating pro-inflammatory cytokines, co-stimulatory molecules, MHC II, and 
chemokines. This leads to reduced activation of effector T cells and immune tolerance to 
intestinal flora. In contrast to the intestine, IL-10 promotes autoimmunity against peripheral nerves. In 
the nerve-draining lymph nodes, IL-10 secreted by T cells leads to STAT3-dependent upregulation of 
S1pr1 in T cells in an autocrine and paracrine fashion. Increased S1PR1 expression in T cells leads to 
increased emigration from lymph nodes and subsequent infiltration of peripheral nerves. Immune 
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